CXCL8 binding nucleic acid
By designing L-nucleic acid molecules with specific nucleotide sequences, high affinity specific binding and inhibition of CXCL8 is achieved, the specific binding and biological stability problems in the prior art are solved, and the choice within the pimolar range is demonstrated Sex and stability for the treatment of CXCL8-related diseases.
Patent Information
- Application Number
- CN201980074218.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-12
- Filing Date
- 2019-11-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-11-12
AI Technical Summary
The prior art is difficult to develop a nucleic acid molecule that specifically binds CXCL8 without interfering with other ELR-positive chemokinetics or receptors, and existing nucleic acid drugs have challenges in biostability and pharmacokinetics, resulting in poor therapeutic effects. good.
An L-nucleic acid molecule is designed that contains specific nucleotide sequences that can specifically bind human CXCL8 with high affinity, inhibit the binding of CXCL8 to its receptor, and show selectivity in the pimolar range, avoiding positive for other ELRs. Chemokine or receptor interaction.
Effective inhibition of CXCL8 was achieved, blocking its chemotaxis, showing high selectivity and stability, potentially used to treat diseases involved in CXCL8, reducing the risk of side effects.
Smart Images

Figure CN113383079B_ABST
Abstract
Description
[0001] The present invention relates to a nucleic acid molecule capable of binding to CXCL8, the nucleic acid molecule is used in a method for treating and / or preventing a disease, the nucleic acid molecule is used in a method for detecting CXCL8, the nucleic acid molecule is used to manufacture a detection means or a biosensor, a pharmaceutical composition comprising the nucleic acid molecule, the use of the nucleic acid molecule for preparing a drug, the use of the nucleic acid molecule for preparing a diagnostic agent, a diagnostic means or a biosensor, the use of the nucleic acid molecule for detecting CXCL8, a kit comprising the nucleic acid molecule, a method for detecting CXCL8 using the nucleic acid molecule, a complex comprising the nucleic acid molecule, a method for screening an antagonist of activity mediated by CXCL8 using the nucleic acid molecule, and a method for detecting the nucleic acid molecule.
[0002] CXCL8 (UniProtKB / Swiss-Prot P10145, IL8_HUMAN; SEQ ID NO: 2), also known as interleukin 8 (abbreviated as IL-8), neutrophil activating protein 1 (abbreviated as NAP-1), monocyte-derived neutrophil chemotactic factor (abbreviated as MDNCF) or granulocyte chemoattractant protein 1 (abbreviated as GCP-1), is a small molecule basic protein belonging to the CXC chemokine subfamily. This subfamily of chemokines has pro-inflammatory and pro-angiogenic properties, characterized by a glutamic acid-leucine-arginine (abbreviated as ELR) motif at the N-terminus. The ELR-positive chemokines CXCL1 (also known as growth-regulated alpha protein, Gro-α, melanoma growth-stimulating activity protein, MGSA or NAP-3), CXCL2 (also known as Gro-β or macrophage inflammatory protein 2-α, MIP2-α), CXCL3 (also known as Gro-γ or MIP2-β), CXCL5 (also known as epithelial cell-derived neutrophil-activating protein 78, ENA-78 or small inducing cytokine B5), CXCL6 (also known as chemokine α3, CKA-3, granulocyte chemoattractant protein 2, GCP-2 or small inducing cytokine B6), CXCL7 (also known as platelet basic protein, PBP, leukocyte-derived growth factor, LDGF, macrophage-derived growth factor, MDGF or small inducing cytokine B7) and CXCL8 are agonists of the receptor CXCR2 (also known as IL8RB, IL8R type 2, CD182, CDw128b or GRO / MGSA receptor). CXCL6, CXCL7, and CXCL8 are agonists of the receptor CXCR1 (also known as IL8RA, IL8R type 1, CD181, or CDw128a). CXCL8 binds to the receptor CXCR1 and the receptor CXCR2 with similar affinity, approximately 4 nM. Binding of CXCL8 to CXCR1 / 2 triggers Gαi-dependent signaling pathways and, for example, induces neutrophil migration, degranulation, and oxidative burst. Phosphorylation, β-arrestin recruitment, and receptor internalization can modulate receptor sensitivity (Ha, Theranostics 2017). CXCL7 and CXCL8 have the highest homology, with 33 identical amino acids. CXCL8 from non-human primates (wild-caught rhesus macaques (macaca mulata), cynomolgus monkeys) shares 95% identity with human CXCL8 (73 of 77 amino acids are identical). Orthologs of CXCL8 are not present in mice and rats.
[0003] CXCL8 is secreted by different cell types including monocytes, macrophages, fibroblasts, endothelial cells and epithelial cells in response to, for example, pathogen-associated molecular pattern (PAMP) molecules (e.g., LPS), pro-inflammatory mediators (e.g., IL-1, IL-6 and TNF-a), hypoxia, reactive oxygen species or environmental stressors (e.g., cigarette smoke) (Ha, Theranostics 2017). CXCL8 acts as a chemotactic and activating cytokine for neutrophils and monocytes and plays an important physiological role in host defense.
[0004] CXCL8 is used as a biomarker for diagnosis, disease status, prognosis, and therapeutic efficacy in infectious diseases with elevated CXCL8 levels has been described in viral infections (e.g., respiratory syncytial virus, herpes simplex virus, hepatitis B and C viruses, human cytomegalovirus), bacterial infections (e.g., Streptococcus pneumoniae and Mycobacterium tuberculosis), and fungal infections (e.g., Candida albicans and Aspergillus fumigatus). In pediatric respiratory syncytial virus (abbreviated as RSV) infection, CXCL8 plasma levels correlate with the severity of the disease. Thus, CXCL8 can be used as a biomarker to assess the severity of RSV infection and guide clinical management. Combined with other immunological biomarkers (i.e., lymphocyte counts and CCL5 plasma levels), the accuracy is improved (Brand, Pediatr Res 2013). Additional examples of the use of CXCL8 as a biomarker in infectious diseases are neonatal sepsis (Zhou, PLoS One 2015), bacterial meningitis (Yao, IntJ Clin Exp Med 2015), pneumonia (Morris, Thorax 2009), and neurosyphilis (Wang, Sci Rep 2016). CXCL8 can also be used as a biomarker in inflammatory diseases including chronic prostatitis, acute pyelonephritis, cystic fibrosis, and various autoimmune diseases (Shahzad, Int Arch Med 2010). In cancer patients, CXCL8 levels are associated with tumor burden and poor outcomes (Sanmamed, Clin Cancer Res 2014). For example, CXCL8 is associated with shorter survival in breast cancer (Fang, Anticancer Res 2017), pancreatic cancer (Chen, World J Gastroenterol 2012), and pediatric sarcoma (Highfill, Sci Transl Med 2014). In melanoma, elevated baseline CXCL8 levels are associated with non-responsiveness to anti-CTLA4 / chemotherapy combination therapy and poorer patient outcomes (Jamal, J Immunother Cancer 2017).
[0005] CXCL8 and its receptors are involved in the pathogenesis of several inflammatory diseases, including respiratory inflammatory diseases (e.g., chronic obstructive pulmonary disease, acute respiratory distress syndrome, asthma, cystic fibrosis, pulmonary fibrosis), skin inflammatory diseases (e.g., neutrophilic dermatosis, psoriasis, bullous pemphigoid), autoimmune diseases (e.g., inflammatory bowel disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis), inflammatory neurological diseases (e.g., neuro-sweet disease, Alzheimer's disease), ischemic diseases (e.g., stroke, myocardial infarction, cerebral ischemia and infarction), and other inflammatory diseases (e.g., atherosclerosis) (Ha, Theranostics 2017; Russo, Expert Rev Clin Immunol 2014). The potential of inhibiting CXCL8 for the treatment of such inflammatory diseases is supported by animal disease models. For example, in rabbits, anti-CXCL8 antibody administration improved LPS-induced dermatitis, LPS-induced pleurisy, LPS / IL-1-induced arthritis, type IC glomerulonephritis, acute lung injury, and lung reperfusion injury (Bao, Int Immunopharmacol 2010; Harada, J Leukoc Biol 1994). CXCR1 / 2 blockade alleviated ischemic brain injury in a rat model (Garau, Cytokine 2005).
[0006] CXCL8 is involved in the occurrence, development and treatment resistance of human cancers, including lung cancer, colon cancer, prostate cancer, pancreatic cancer, breast cancer, ovarian cancer and melanoma, and promotes tumor growth and metastasis (Brat, Neuro Oncol 2005; Ha, Theranostics 2017; Koch, Science 1992; Li, Angiogenesis 2005; Liu, Cytokine Growth Factor Rev 2016; Xu, Oncol Res 2000). The pro-oncogenic mechanisms of CXCL8 include stimulation of angiogenesis, self-renewal of cancer stem cells, epithelial cell to mesenchymal cell transformation and the formation of an immunosuppressive tumor microenvironment (Ginestier, J Clin Invest 2010; Visvader, Nat Rev Cancer 2008; David, Vaccines 2016). The potential of inhibiting CXCL8 for the treatment of human cancer is supported by animal disease models. For example, CXCL8 knockdown reduces the growth of chemotherapy-resistant ovarian cancer cells (Merritt, J Natl Cancer Inst 2008). In ovarian and prostate cancer models, inhibition of CXCL8 enhances the anti-angiogenic response triggered by docetaxel (Campbell, Pharmaceuticals 2013). In tumors deficient in phosphatase and tensin homolog (PTEN), overexpression of CXCL8 enhances cancer cell viability and promotes the formation of treatment-resistant tumors (Campbell, Pharmaceuticals 2013; Maxwell, Eur Urol 2013; Maxwell, Oncotarget 2014). Inhibition of CXCL8 signaling increases the sensitivity of PTEN-deficient and p53-mutated cancer cells to DNA damaging agents, antimetabolites, or androgen receptor targeting strategies (Campbell, Pharmaceuticals 2013). In mouse models of rhabdomyosarcoma and pancreatic ductal adenocarcinoma, CXCR2 blockade enhanced the efficacy of immune checkpoint inhibitors against PD-1 (Highfill, Sci Transl Med 2014; Steele, Cancer Cell 2016).
[0007] Several compounds are known to target CXCL8 or to target one or both of the corresponding receptors CXCR1 and CXCR2 and have been successfully tested in in vivo models. Some of these compounds are also being tested in clinical trials. Antagonists of CXCR1 and / or CXCR2, namely reparixin, ladarixin, danirixin, navarixin, SX-682 and AZD-5069, are being tested in clinical trials for islet transplantation, organ transplantation, type 1 diabetes, COPD, asthma, bronchiectasis, psoriasis, bullous pemphigoid and cancer. The CXCR1 / 2 antagonist reparixin is further being tested clinically in patients with metastatic triple-negative breast cancer. The CXCR2 antagonist AZD-5069 is being tested in solid cancers in combination with the anti-PD-L1 durvalumab or chemotherapy regimens.
[0008] Although ELR-positive chemokines share receptors CXCR1 and CXCR2, these chemokines have different expression patterns, in vivo distribution (extracellular matrix binding properties) and mechanisms of interaction with receptors (Feniger-Barish, Cytokine 1999; Sawant, Sci Rep 2016). Little is known about the physiological functions of different ELR-positive chemokine family members. Therefore, compared with the extensive blockade of CXCR1 / CXCR2 blockade, selective inhibition of disease-promoting CXCL8 may be more effective for disease treatment and may reduce the risk of side effects. For example, CXCL8 is necessary for maintaining cancer stem cells, but CXCL1 is not (Liotti F et al., Stem Cells 2017; 35: 135-146). In infection, chemokines have overlapping activities. Thus, widespread inhibition of ELR-positive chemokines (e.g., simultaneous inhibition of CXCL8 and CXCL1) may be associated with an increased risk of infection (Yung SC and Murphy PM; frontiers in Immunology, September 2012, Vol. 3, Art. 276). CXCR1 / 2 ligands share a common N-terminal ELR motif that can serve as a binding epitope (described in U.S. Pat. No. 9,783,605). When trying to identify a compound that will selectively bind to and inhibit CXCL8 without interfering with other ELR-positive chemokines, the presence of this common structural feature in the CXCR1 / 2 ligands CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 is a challenge.
[0009] Antibodies that bind to CXCL8 but not to the ELR-positive chemokines CXCL1 (also known as somatomedin α, Gro-α) and CXCL2 (also known as somatomedin β, Gro-β) have been identified (Skov, J Immunol 2008). To date, monoclonal antibodies specific for CXCL8 have not shown efficacy in clinical trials, which may be related to the pharmacological properties of this class of substances, including their pharmacokinetic properties, biodistribution and elimination. For example, the high production rate of chemokines may lead to rapid saturation of therapeutic antibodies and insufficient efficacy under long dosing intervals in routine use. Moreover, antibodies may potentially not interfere with the binding of chemokines to glycosaminoglycans, which results in a lack of disruption of chemokine gradients and insufficient inhibition of leukocyte migration and infiltration. Nucleic acids preferentially bind to the glycosaminoglycan binding sites of proteins (Oberthur, Nat Commun 2015). Therefore, other classes of substances such as nucleic acids may be more advantageous for targeted therapy against CXCL8.
[0010] Nucleic acids are sensitive to degradation by enzymes (nucleases) present in body fluids. This lack of biological stability has hampered the preparation of nucleic acid-based drugs for the treatment of humans and the preparation of nucleic acid-based diagnostic agents for disease identification and / or treatment. Chemical modification can improve the stability of nucleic acids, but the stability provided may still be insufficient for use as pharmaceutical agents. For example, nucleic acids with 2'-fluoro-modified pyrimidines exhibit plasma half-lives comparable to pure DNA nucleic acids and require 2'-O-methyl modification to achieve longer half-lives (Kratschmer, Nucleic Acid Ther 2017). As the first approved therapeutic aptamer, pegaptanib sodium (Macugen) is stabilized by a combination of 2'-fluoro-pyrimidine, 2'-O-methyl-purine, and 3'-end capping. Moreover, chemical modifications may be accompanied by an increased risk of side effects when used in pharmaceutical production. In contrast, non-natural L-nucleic acids have high biological stability and have shown safety, good tolerability, and efficacy in clinical trials (Ludwig, Leukemia 2017; Menne, Nephrol Dial Transplant 2016).
[0011] CXCL8-binding 2'-fluoropyrimidine RNA-aptamers have been described previously (Sung, Biomaterials 2014). However, the high binding affinity of one of the described aptamers, aptamer 8A-35, did not translate into functional improvement in functional assays, with an IC50 of >125 nM for inhibition of CXCL8-induced neutrophil migration. Semiquantitative analysis showed that the aptamer precursor had no or low binding to the ELR-positive chemokines CXCL1 (also known as Gro-α) and CXCL2 (also known as Gro-β).
[0012] The problem underlying the present invention is to provide a nucleic acid molecule, preferably an L-nucleic acid, which specifically interacts with CXCL8, preferably does not specifically interact with other ELR-positive chemokines, and more preferably does not interact with ELR-positive chemokines binding to the receptors CXCR1 and / or CXCR2.
[0013] Another underlying problem of the present invention is to provide a nucleic acid molecule, preferably an L-nucleic acid molecule, which binds to CXCL8 with high affinity, such that it effectively inhibits CXCL8-stimulated chemotaxis, preferably with an inhibition constant in the single-digit nanomolar range, more preferably in the picomolar range.
[0014] A further underlying problem of the present invention is to provide a nucleic acid molecule, preferably an L-nucleic acid molecule, for the preparation of a medicament for the treatment of human and / or non-human diseases, wherein said diseases are characterized by the direct or indirect involvement of CXCL8 in the pathogenesis of such diseases, preferably at least to the extent that antagonism or inhibition of CXCL8 produces a therapeutic effect.
[0015] A further problem underlying the present invention is to provide a nucleic acid molecule, preferably an L-nucleic acid molecule, for the preparation of a diagnostic agent for the identification, diagnosis and / or treatment of diseases characterized by the direct or indirect involvement of CXCL8 in the pathogenesis of such diseases.
[0016] These and other main underlying problems of the invention are solved by the subject matter of the attached independent claims. Preferred embodiments can be taken from the dependent claims.
[0017] More specifically, the problem underlying the present invention is solved in the following first aspect: an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central nucleotide segment, wherein the central nucleotide segment comprises the following nucleotide sequence:
[0018] 5'-GGAAGUACGUGGAAAGCCRA(X U )RAGUGUGUCCCG-3'[SEQ.ID.NO:27], wherein X UIs U or does not exist.
[0019] More specifically, the problem underlying the present invention is solved in the following second aspect: The L-nucleic acid molecule of the first aspect (including any embodiment thereof) is used in a method for the treatment and / or prevention of a disease.
[0020] More specifically, the problem underlying the present invention is solved in the following third aspect: The L-nucleic acid molecule of the first aspect (including any embodiment thereof) is used in a method for detecting CXCL8.
[0021] More specifically, the problem underlying the present invention is solved in the following fourth aspect: The L-nucleic acid molecule of the first aspect (including any embodiment thereof) is used for preparing a detection means or a biosensor.
[0022] More specifically, the problem underlying the present invention is solved in the following fifth aspect: a pharmaceutical composition comprising an L-nucleic acid molecule according to the first aspect (including any embodiment thereof) and optionally further components, wherein the further components are selected from the group comprising a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier and a pharmaceutically active agent.
[0023] More specifically, the problem underlying the present invention is solved in the following sixth aspect: Use of an L-nucleic acid molecule according to the first aspect (including any embodiment thereof) for the preparation of a medicament.
[0024] More specifically, the problem underlying the present invention is solved in the following seventh aspect: Use of an L-nucleic acid molecule according to the first aspect (including any embodiment thereof) for the preparation of a diagnostic agent, a diagnostic means or a biosensor.
[0025] More specifically, the problem underlying the present invention is solved in the following eighth aspect: Use of an L-nucleic acid molecule according to the first aspect (including any embodiment thereof) for detecting CXCL8, preferably human CXCL8.
[0026] More specifically, the problem underlying the present invention is solved in the following ninth aspect: a kit for detecting CXCL8, wherein the kit comprises an L-nucleic acid molecule according to the first aspect, including any embodiment thereof, and at least instructions or a reaction container.
[0027] More specifically, the problem underlying the present invention is solved in the following tenth aspect: a method for detecting CXCL8 in a sample using an L-nucleic acid as defined according to the first aspect (including any embodiment thereof), wherein the method comprises the following steps:
[0028] a) providing a sample with an unknown concentration of CXCL8;
[0029] b) contacting the sample or a dilution thereof with a diagnostic agent, diagnostic means or biosensor as defined in the seventh aspect (including any embodiment thereof);
[0030] c) measuring a signal using the diagnostic agent, diagnostic means or biosensor defined in the seventh aspect (including any embodiment thereof);
[0031] d) optionally, comparing the signal to a reference;
[0032] Optionally, the CXCL8 concentration in the sample with unknown CXCL8 concentration is determined by comparison with the signal obtained from at least one sample with known CXCL8 concentration, preferably at least one sample with known CXCL8 concentration is subjected to steps b) to c).
[0033] More specifically, the problem underlying the present invention is solved in the following eleventh aspect: a complex comprising an L-nucleic acid molecule according to the first aspect (including any embodiment thereof) and CXCL8, preferably, wherein the complex is a crystalline complex.
[0034] More specifically, the problem underlying the present invention is solved in the following twelfth aspect: a method for screening an antagonist of CXCL8-mediated activity, comprising the following steps:
[0035] - providing candidate antagonists of CXCL8-mediated activity,
[0036] - providing an L-nucleic acid molecule according to the first aspect, including any embodiment thereof,
[0037] - providing an assay system that provides a signal in the presence of an antagonist of CXCL8-mediated activity, and
[0038] - Determining whether a candidate antagonist of CXCL8-mediated activity is an antagonist of CXCL8-mediated activity.
[0039] More specifically, the problem underlying the present invention is solved in the following thirteenth aspect: a method for detecting an L-nucleic acid molecule according to the first aspect (including any embodiment thereof) in a sample, wherein the method comprises the following steps:
[0040] a) providing a capture probe and a detection probe, wherein the capture probe is at least partially complementary to a first part of an L-nucleic acid molecule according to the first aspect (including any embodiment thereof), wherein the detection probe is at least partially complementary to a second part of an L-nucleic acid molecule according to the first aspect (including any embodiment thereof), or alternatively, the capture probe is at least partially complementary to a second part of an L-nucleic acid molecule according to the first aspect (including any embodiment thereof), and the detection probe is at least partially complementary to a first part of an L-nucleic acid molecule according to the first aspect (including any embodiment thereof);
[0041] b) adding the capture probe and the detection probe, separately or in combination, to a sample containing the L-nucleic acid molecule according to the first aspect (including any embodiment thereof) or assumed to contain the L-nucleic acid molecule according to the first aspect (including any embodiment thereof);
[0042] c) reacting the capture probe and the detection probe simultaneously or sequentially in any order with an L-nucleic acid molecule according to the first aspect (including any embodiment thereof);
[0043] d) optionally, detecting whether the capture probe provided in step a) hybridizes to the L-nucleic acid molecule according to the first aspect (including any embodiment thereof); and
[0044] e) detecting the complex formed in step c), which consists of the L-nucleic acid molecule according to the first aspect (including any embodiment thereof) and the capture probe and the detection probe.
[0045] More specifically, the present invention is also solved by the following embodiments 1-103, wherein embodiment 1 corresponds to the first aspect, embodiment 47 corresponds to the second aspect, embodiment 49 corresponds to the third aspect, embodiment 50 corresponds to the fourth aspect, embodiment 51 corresponds to the fifth aspect, embodiment 53 corresponds to the sixth aspect, embodiment 56 corresponds to the seventh aspect, embodiment 79 corresponds to the eighth aspect, embodiment 96 corresponds to the ninth aspect, embodiment 97 corresponds to the tenth aspect, embodiment 98 corresponds to the eleventh aspect, embodiment 99 corresponds to the twelfth aspect, and embodiment 100 corresponds to the thirteenth aspect:
[0046] Embodiment 1: An L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central nucleotide segment, wherein the central nucleotide segment comprises the following nucleotide sequence:
[0047] 5'-GGAAGUACGUGGAAAGCCRA(X U)RAGUGUGUCCCG-3'[SEQ.ID.NO:27], wherein X U Is U or does not exist.
[0048] Embodiment 2: The L-nucleic acid molecule of embodiment 1, wherein the central nucleotide segment comprises a nucleotide sequence selected from the group consisting of:
[0049] a)5'GGAAGUACGUGGAAAGCCAAUGAGUGUGUCCCG 3'[SEQ.
[0050] ID.NO:28],
[0051] b)5'GGAAGUACGUGGAAAGCCGAUGAGUGUGUCCCG 3'[SEQ.
[0052] ID.NO:29] and
[0053] c)5'GGAAGUACGUGGAAAGCCGAAAGUGUGUCCCG 3'[SEQ.
[0054] ID.NO:30].
[0055] Embodiment 3: The L-nucleic acid molecule of embodiment 2, wherein the central nucleotide segment comprises the following nucleotide sequence:
[0056] 5'GGAAGUACGUGGAAAGCCGAAAGUGUGUCCCG 3'[SEQ.ID.NO:30] or 5'GGAAGUACGUGGAAAGCCAAUGAGUGUGUCCCG 3'[SEQ.ID.NO:28], preferably 5'GGAAGUACGUGGAAAGCCGAAAGUGUGUCCCG3'[SEQ.ID.NO:30].
[0057] Embodiment 4: The L-nucleic acid molecule of any one of embodiments 1 to 3, wherein the L-nucleic acid molecule comprises a first terminal nucleotide segment, the central nucleotide segment, and a second terminal nucleotide segment in a 5'->3' direction, wherein
[0058] The first terminal nucleotide segment comprises 3 to 6 nucleotides, and
[0059] The second terminal nucleotide segment comprises 3 to 6 nucleotides,
[0060] Preferably,
[0061] The first terminal nucleotide segment comprises 5 to 6 nucleotides, and
[0062] The second terminal nucleotide segment comprises 5 to 6 nucleotides,
[0063] More preferably,
[0064] The first terminal nucleotide segment comprises 5 nucleotides, and
[0065] The second terminal stretch of nucleotides comprises 5 nucleotides.
[0066] Embodiment 5: The L-nucleic acid molecule of embodiment 4, wherein the first terminal nucleotide segment comprises a nucleotide sequence of 5'Z1Z2Z3Z4Z5C 3' and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GZ6Z7Z8Z9Z 10 The nucleotide sequence of 3'
[0067] in,
[0068] Z1 is G or does not exist, Z2 is S or does not exist, Z3 is K or does not exist, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M or does not exist, Z9 is S or does not exist, and Z 10 C or not present;
[0069] Preferably,
[0070] a) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0071] b) Z1 is absent, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0072] c) Z1 is not present, Z2 is not present, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is not present, and Z 10 does not exist; or
[0073] d) Z1 is absent, Z2 is absent, Z3 is absent, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is absent, Z9 is absent, and Z 10 does not exist; or
[0074] e) Z1 is absent, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0075] f) Z1 is absent, Z2 is absent, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0076] g) Z1 is absent, Z2 is absent, Z3 is absent, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0077] h) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0078] i) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is absent, and Z 10 does not exist; or
[0079] j) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is absent, Z9 is absent, and Z 10 does not exist; or
[0080] k) Z1 is not present, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is not present, and Z 10 does not exist; or
[0081] l) Z1 is not present, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is not present, Z9 is not present, and Z 10 does not exist; or
[0082] m) Z1 is absent, Z2 is absent, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0083] n) Z1 is absent, Z2 is absent, Z3 is absent, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0084] o) Z1 is not present, Z2 is not present, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is not present, Z9 is not present, and Z 10 does not exist; or
[0085] p) Z1 is not present, Z2 is not present, Z3 is not present, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is not present, and Z 10 Does not exist.
[0086] Embodiment 6: The L-nucleic acid molecule according to any one of embodiments 4 to 5, wherein
[0087] a) the first terminal nucleotide segment comprises a nucleotide sequence of 5'CUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAG 3';
[0088] b) the first terminal nucleotide segment comprises a nucleotide sequence of 5'GCUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAGC 3'; or
[0089] c) the first terminal nucleotide segment comprises a nucleotide sequence of 5'GCUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUGAGC 3';
[0090] d) the first terminal nucleotide segment comprises a nucleotide sequence of 5'GUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAC 3';
[0091] e) the first terminal nucleotide segment comprises a nucleotide sequence of 5'UGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCA 3';
[0092] f) the first terminal nucleotide segment comprises a nucleotide sequence of 5'GGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCC 3';
[0093] g) the first terminal nucleotide segment comprises a nucleotide sequence of 5'GCAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUGC 3';
[0094] h) the first terminal nucleotide segment comprises a nucleotide sequence of 5'GGUC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GACC 3';
[0095] i) the first terminal nucleotide segment comprises a nucleotide sequence of 5'UGGC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GCCA 3';
[0096] j) the first terminal nucleotide segment comprises a nucleotide sequence of 5'GAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUC 3';
[0097] Preferably,
[0098] The first terminal nucleotide segment comprises a nucleotide sequence of 5'CUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAG 3';
[0099] or
[0100] The first terminal nucleotide segment comprises a nucleotide sequence of 5'GCUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAGC 3';
[0101] or
[0102] The first terminal nucleotide segment comprises a nucleotide sequence of 5'GUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAC 3';
[0103] More preferably,
[0104] The first terminal nucleotide segment comprises a nucleotide sequence of 5'CUGAC 3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAG 3';
[0105] or
[0106] The first terminal nucleotide stretch comprises a nucleotide sequence of 5'GUGAC 3', and the second terminal nucleotide stretch comprises a nucleotide sequence of 5'GUCAC 3'.
[0107] Embodiment 7: The L-nucleic acid molecule according to any one of Embodiments 1 to 6, wherein the L-nucleic acid molecule comprises 40 to 45 nucleotides, preferably 42 to 45 nucleotides, more preferably 42 nucleotides.
[0108] Embodiment 8: The L-nucleic acid molecule of any one of Embodiments 1 to 7, wherein the L-nucleic acid molecule consists of ribonucleotides.
[0109] Embodiment 9: An L-nucleic acid molecule according to any one of embodiments 1 to 8, wherein the L-nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ.ID.No: 14 to 26 and SEQ.ID.No: 39 to 44, or the L-nucleic acid molecule comprises an L-nucleic acid molecule having at least 75% identity with an L-nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ.ID.No: 14 to 26 and SEQ.ID.No: 39 to 44, or the L-nucleic acid molecule comprises an L-nucleic acid molecule homologous to an L-nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ.ID.No: 14 to 26 and SEQ.ID.No: 39 to 44, wherein the homology is at least 75%.
[0110] Embodiment 10: The L-nucleic acid molecule of embodiment 9, wherein the L-nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ.ID.NO:16, SEQ.ID.NO:17, SEQ.ID.NO:25, SEQ.ID.NO:26, SEQ.ID.NO:39, SEQ.ID.NO:40, SEQ.ID.NO:20, and SEQ.ID.No:41 to 44, or the L-nucleic acid molecule comprises an L-nucleic acid molecule having at least 75% identity with a nucleotide sequence selected from the group consisting of SEQ.ID.NO:16, SEQ.ID.NO:17, SEQ.ID.NO:25, SEQ.ID.NO:26, SEQ.ID.NO:39, SEQ.ID.NO:40, SEQ.ID.NO:20, and SEQ.ID.No:41 to 44. .NO:25, SEQ.ID.NO:26, SEQ.ID.NO:39, SEQ.ID.NO:40, SEQ.ID.NO:20 and SEQ.ID.No:41 to 44, or the L-nucleic acid molecule comprises an L-nucleic acid molecule homologous to an L-nucleic acid molecule containing a nucleotide sequence selected from the following group: SEQ.ID.NO:16, SEQ.ID.NO:17, SEQ.ID.NO:25, SEQ.ID.NO:26, SEQ.ID.NO:39, SEQ.ID.NO:40, SEQ.ID.NO:20 and SEQ.ID.No:41 to 44, wherein the homology is at least 75%.
[0111] Embodiment 11: The L-nucleic acid molecule of any one of embodiments 1 to 10, wherein the L-nucleic acid molecule is capable of binding to CXCL8, wherein preferably, CXCL8 is human CXCL8, monkey CXCL8, rabbit CXCL8, pig CXCL8, dog CXCL8, sheep CXCL8 or guinea pig CXCL8.
[0112] Embodiment 12: The L-nucleic acid molecule of any one of Embodiments 1 to 11, wherein the L-nucleic acid molecule is capable of specifically binding to CXCL8, preferably human CXCL8, monkey CXCL8, rabbit CXCL8, pig CXCL8, dog CXCL8, sheep CXCL8 or guinea pig CXCL8, more preferably human CXCL8.
[0113] Embodiment 13: The L-nucleic acid molecule of any one of Embodiments 1 to 12, wherein the L-nucleic acid molecule does not bind or is unable to bind to an ELR-positive CXC chemokine different from CXCL8, wherein the ELR-positive CXC chemokine different from CXCL8 is preferably selected from the group consisting of CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL7.
[0114] Embodiment 14: The L-nucleic acid molecule described in Embodiment 13, wherein the L-nucleic acid molecule does not bind or is unable to bind to an ELR-positive human CXC chemokine different from human CXCL8, wherein the ELR-positive human CXC chemokine different from human CXCL8 is preferably selected from the group consisting of human CXCL1, human CXCL2, human CXCL3, human CXCL5, human CXCL6 and human CXCL7.
[0115] Embodiment 15: The L-nucleic acid molecule of any one of Embodiments 1 to 14, wherein the binding affinity of the L-nucleic acid molecule to human CXCL8 is 10 nM or lower, preferably 1 nM or lower, more preferably 100 pM or lower, and most preferably 30 pM or lower, expressed as KD.
[0116] Embodiment 16: The L-nucleic acid molecule of any one of Embodiments 1 to 15, wherein the binding affinity of the L-nucleic acid molecule to human CXCL8 is 10 nM or lower, preferably 1 nM or lower, more preferably 100 pM or lower, and most preferably 30 pM or lower, expressed as IC50.
[0117] Embodiment 17: The L-nucleic acid molecule of any one of Embodiments 1 to 16, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is expressed as a KD of 100 nM or higher, preferably 500 nM or higher, and more preferably 1000 nM or higher.
[0118] Embodiment 18: The L-nucleic acid molecule of any one of Embodiments 1 to 17, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is 100 nM or higher, preferably 500 nM or higher, and more preferably 1000 nM or higher, expressed as IC50.
[0119] Embodiment 19: The L-nucleic acid molecule of any one of Embodiments 1 to 18, wherein the binding affinity of the L-nucleic acid molecule to human CXCL8 is expressed as 10 nM or less, preferably 1 nM or less, more preferably 100 pM or less, and most preferably 30 pM or less, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is expressed as 100 nM or more, preferably 500 nM or more, and more preferably 1000 nM or more,
[0120] and / or
[0121] The binding affinity of the L-nucleic acid molecule to human CXCL8 is expressed as an IC50 of 10 nM or less, preferably 1 nM or less, more preferably 100 pM or less, and most preferably 30 pM or less, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is expressed as an IC50 of 100 nM or more, preferably 500 nM or more, and more preferably 1000 nM or more.
[0122] Embodiment 20: The L-nucleic acid molecule of any one of Embodiments 15 to 19, wherein the binding affinity is determined at room temperature, preferably at 25°C.
[0123] Embodiment 21: The L-nucleic acid molecule of any one of Embodiments 15 to 19, wherein the binding affinity is determined at 37°C.
[0124] Embodiment 22: The L-nucleic acid molecule of any one of Embodiments 1 to 21, wherein the L-nucleic acid molecule is an antagonist of activity mediated by CXCL8, and the CXCL8 is preferably human CXCL8, monkey CXCL8, rabbit CXCL8, pig CXCL8, dog CXCL8, sheep CXCL8 or guinea pig CXCL8, more preferably human CXCL8.
[0125] Embodiment 23: The L-nucleic acid molecule described in Embodiment 22, wherein the L-nucleic acid molecule is not an antagonist of an ELR-positive human CXC chemokine other than human CXCL8, or is unable to antagonize the activity mediated by an ELR-positive CXC chemokine other than CXCL8, wherein the ELR-positive CXC chemokine other than CXCL8 is preferably selected from the group consisting of CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL7.
[0126] Embodiment 24: The L-nucleic acid molecule described in Embodiment 23, wherein the L-nucleic acid molecule is not an antagonist of an ELR-positive human CXC chemokine different from human CXCL8, or is unable to antagonize the activity mediated by an ELR-positive human CXC chemokine different from human CXCL8, wherein the ELR-positive human CXC chemokine different from human CXCL8 is preferably selected from the group consisting of human CXCL1, human CXCL2, human CXCL3, human CXCL5, human CXCL6 and human CXCL7.
[0127] Embodiment 25: The L-nucleic acid molecule of any one of Embodiments 22 to 24, wherein the antagonistic activity of the L-nucleic acid molecule against the activity mediated by human CXCR1 and / or CXCR2 is expressed as an IC50 of 10 nM or less, preferably 1 nM or less, more preferably 100 pM or less, and most preferably 30 pM or less.
[0128] Embodiment 26: The L-nucleic acid molecule of any one of Embodiments 22 to 25, wherein the antagonistic activity of the L-nucleic acid molecule on activity mediated by human CXCL8 is determined at 37°C.
[0129] Embodiment 27: The L-nucleic acid molecule of any one of Embodiments 1 to 26, wherein the L-nucleic acid molecule comprises a modifying group.
[0130] Embodiment 28: The L-nucleic acid molecule of Embodiment 27, wherein the modifying group is coupled to the 5'-terminal nucleotide and / or the 3'-terminal nucleotide of the L-nucleic acid molecule, and / or is coupled to a nucleotide of the L-nucleic acid molecule between the 5'-terminal nucleotide of the L-nucleic acid molecule and the 3'-terminal nucleotide of the L-nucleic acid molecule.
[0131] Embodiment 29: The L-nucleic acid molecule of any one of Embodiments 27 and 28, wherein the modifying group is coupled to the L-nucleic acid molecule via a linker.
[0132] Embodiment 30: The L-nucleic acid molecule of Embodiment 29, wherein the linker is a hydrophilic linker, preferably, the hydrophilic linker comprises one or more ethylene glycol units, more preferably, the hydrophilic linker comprises triethylene glycol, hexaethylene glycol or polyethylene glycol.
[0133] Embodiment 31: The L-nucleic acid molecule of Embodiment 29, wherein the linker is a biodegradable linker.
[0134] Embodiment 32: The L-nucleic acid molecule of any one of Embodiments 27 to 31, wherein the excretion rate of the L-nucleic acid molecule comprising the modification group from the organism is reduced compared to the excretion rate of the L-nucleic acid molecule not containing the modification group.
[0135] Embodiment 33: The L-nucleic acid molecule of any one of Embodiments 27 to 31, wherein the L-nucleic acid molecule comprising the modification group has a longer retention time in the organism than the L-nucleic acid molecule not containing the modification group.
[0136] Embodiment 34: The L-nucleic acid molecule according to any one of Embodiments 32 to 33, wherein the organism is a human or animal body, preferably a human body.
[0137] Embodiment 35: The L-nucleic acid molecule of any one of Embodiments 27 and 34, wherein the modification group is selected from the group comprising biodegradable modifications and non-biodegradable modifications, preferably, the modification group is selected from the group comprising polyethylene glycol, linear polyethylene glycol, branched polyethylene glycol, hydroxyethyl starch, peptides, proteins, polysaccharides, sterols, polyoxypropylene, polyoxyamidates and poly(2-hydroxyethyl)-L-glutamine.
[0138] Embodiment 36: The L-nucleic acid molecule of embodiment 35, wherein the modifying group is polyethylene glycol, preferably linear polyethylene glycol or branched polyethylene glycol, wherein preferably, the molecular weight of the polyethylene glycol is about 20,000 to about 120,000 Da, more preferably about 30,000 to about 80,000 Da, and most preferably about 40,000 Da.
[0139] Embodiment 37: The L-nucleic acid molecule of Embodiment 36, wherein the molecular weight of the polyethylene glycol is about 20,000 to about 120,000 Da, preferably about 30,000 to about 80,000 Da, and more preferably about 40,000 Da.
[0140] Embodiment 38: The L-nucleic acid molecule of Embodiment 35, wherein the modifying group is hydroxyethyl starch, wherein preferably, the molecular weight of hydroxyethyl starch is about 50 to about 1000 kDa, more preferably about 100 to about 700 kDa, and most preferably 200 to 500 kDa.
[0141] Embodiment 39: The L-nucleic acid molecule of any one of Embodiments 27 to 31, wherein the modification group is used for immobilization of the L-nucleic acid molecule.
[0142] Embodiment 40: The L-nucleic acid molecule of Embodiment 39, wherein the immobilization comprises covalent attachment of the L-nucleic acid molecule to a surface, wherein preferably, the surface is a surface of a reaction vessel, a surface of a device in a reaction vessel, or a surface of a biosensor.
[0143] Embodiment 41: The L-nucleic acid molecule of Embodiment 39, wherein the immobilization comprises non-covalent attachment of the L-nucleic acid molecule to a surface, wherein preferably, the surface is the surface of a reaction vessel, the surface of a device in a reaction vessel, or the surface of a biosensor.
[0144] Embodiment 42: The L-nucleic acid molecule of any one of embodiments 39 to 41, wherein the modification group is selected from the group comprising: carboxyl, hydroxyl, phosphatidyl, sulfonate, amine, thiol, epoxide, alkyne, strained cycloalkyne, maleimide, azide, hydrazide, wherein preferably, the strained cycloalkyne is selected from the group comprising: dibenzocyclooctyl (DBCO), bicyclo[6.1.0]non-4-yne (BCN) and azadibenzocyclooctyne (ADIBO).
[0145] Embodiment 43: The L-nucleic acid molecule of Embodiment 42, wherein the modifying group is a strained cycloalkyne, preferably dibenzocyclooctyl (DBCO).
[0146] Embodiment 44: The L-nucleic acid molecule of Embodiment 41, wherein the modification group is biotin, bromodeoxyuridine, digoxigenin or oligonucleotide, preferably, the modification group is biotin.
[0147] Embodiment 45: The L-nucleic acid molecule of any one of Embodiments 27 to 31, wherein the modification group allows detection of the L-nucleic acid molecule, preferably, the modification group is a label.
[0148] Embodiment 46: The L-nucleic acid molecule of Embodiment 45, wherein the label is selected from the group consisting of biotin, bromodeoxyuridine, digoxigenin, oligonucleotides, fluorescent labels, electrochemiluminescent labels, radioactive labels, enzyme labels, UV labels, colloidal gold, nanoparticles, and chelator molecular labels.
[0149] Embodiment 47: The L-nucleic acid molecule according to any one of Embodiments 1 to 46, for use in a method for treating and / or preventing a disease.
[0150] Embodiment 48: An L-nucleic acid molecule for use according to embodiment 47, wherein the disease is associated with a CXCL8-mediated pathogenesis and / or is selected from the group comprising inflammatory diseases and cancer, wherein preferably, the inflammatory disease is an inflammatory disease of the respiratory system, an inflammatory disease of the skin, an autoimmune disease, an inflammatory neurological disease, an ischemic disease, atherosclerosis, islet transplant rejection, organ transplant rejection, delayed organ function, spinal cord injury or cystitis.
[0151] Embodiment 49: The L-nucleic acid molecule of any one of Embodiments 1 to 47, which is used in a method for detecting CXCL8.
[0152] Embodiment 50: The L-nucleic acid molecule according to any one of Embodiments 1 to 47, which is used for preparing a detection means or a biosensor.
[0153] Embodiment 51: A pharmaceutical composition comprising an L-nucleic acid molecule as defined in any one of embodiments 1 to 50 and optionally further components, wherein the further components are selected from the group comprising a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier and a pharmaceutically active agent.
[0154] Embodiment 52: The pharmaceutical composition of Embodiment 51, wherein the pharmaceutical composition comprises the L-nucleic acid molecule as defined in any one of Embodiments 1 to 50 and a pharmaceutically acceptable carrier.
[0155] Embodiment 53: Use of the L-nucleic acid molecule according to any one of Embodiments 1 to 50 for the preparation of a medicament.
[0156] Embodiment 54: The use of Embodiment 53, wherein the medicament is for use in human medicine or for use in veterinary medicine.
[0157] Embodiment 55: The use described in Embodiment 54, wherein the agent is used to treat and / or prevent a disease associated with a CXCL8-mediated pathogenesis, and / or a disease selected from the group consisting of inflammatory diseases and cancer, wherein preferably, the inflammatory disease is an inflammatory disease of the respiratory system, an inflammatory disease of the skin, an autoimmune disease, an inflammatory neurological disease, an ischemic disease, atherosclerosis, islet transplant rejection, organ transplant rejection, delayed organ function, spinal cord injury or cystitis.
[0158] Embodiment 56: Use of the L-nucleic acid molecule according to any one of Embodiments 1 to 50 for preparing a diagnostic agent, a diagnostic means or a biosensor.
[0159] Embodiment 57: The use of Embodiment 56, wherein the diagnostic agent or diagnostic means has a surface on the reaction vessel or a surface on a device in the reaction vessel.
[0160] Embodiment 58: The use of Embodiment 56, wherein the biosensor has a surface.
[0161] Embodiment 59: The use according to any one of Embodiments 56 to 58, wherein the diagnostic agent, diagnostic means or biosensor is suitable for directly or indirectly detecting CXCL8, preferably human CXCL8.
[0162] Embodiment 60: The use of any one of Embodiments 56 to 57, wherein CXCL8 is detected by direct binding in a sandwich binding assay or in a competition binding assay.
[0163] Embodiment 61: The use of Embodiment 60, wherein the direct binding comprises a detection method using only the L-nucleic acid molecule of any one of Embodiments 1 to 50 and does not use or involve the use of a second molecule that interacts with CXCL8 and is different from the L-nucleic acid molecule of any one of Embodiments 1 to 50.
[0164] Embodiment 62: The use of Embodiment 60, wherein the sandwich assay is a sandwich hybridization assay, wherein the L-nucleic acid molecule of any one of Embodiments 1 to 50 is immobilized on a surface, and the complex of the L-nucleic acid molecule of any one of Embodiments 1 to 50 and CXCL8 is detected by a detection means, wherein the one or more epitopes of CXCL8 bound by the detection means are different from the one or more epitopes bound by the L-nucleic acid molecule of any one of Embodiments 1 to 50.
[0165] Embodiment 63: The use described in Embodiment 60, wherein the sandwich assay is a sandwich hybridization assay, wherein a means is immobilized on a surface, the one or more epitopes of CXCL8 bound by the means being different from the one or more epitopes bound by the L-nucleic acid molecule described in any one of Embodiments 1 to 50, and the complex of the means and CXCL8 is detected by the L-nucleic acid molecule described in any one of Embodiments 1 to 50.
[0166] Embodiment 64: The use of embodiment 60, wherein in a competitive binding assay, the L-nucleic acid molecule of any one of embodiments 1 to 50 is immobilized on a surface, and the binding of the L-nucleic acid molecule of any one of embodiments 1 to 50 to CXCL8 is competed by an oligonucleotide probe (at least partially complementary to the L-nucleic acid molecule of any one of embodiments 1 to 50) or by CXCL8, preferably the complementarity is base complementarity, more preferably the complementarity is based on Watson-Crick base pairing.
[0167] Embodiment 65: The use described in embodiment 60, wherein in the competitive binding assay, the L-nucleic acid molecule of any one of embodiments 1 to 50 is not immobilized on a surface, and the binding of the L-nucleic acid molecule of any one of embodiments 1 to 50 to CXCL8 is competed by an oligonucleotide probe (complementary to the L-nucleic acid molecule of any one of embodiments 1 to 50) or by CXCL8, wherein preferably the oligonucleotide probe complementary to the L-nucleic acid molecule of any one of embodiments 1 to 50 or CXCL8 is immobilized on a surface, preferably the complementarity is base complementarity, more preferably the complementarity is based on Watson-Crick base pairing.
[0168] Embodiment 66: The use according to any one of embodiments 62 to 65, wherein the L-nucleic acid molecule according to any one of embodiments 39 to 44 is used for immobilization on a surface.
[0169] Embodiment 67: The use of any one of Embodiments 57 to 66, wherein the surface, preferably the surface of the biosensor, is selected from the group consisting of gold, silver, titanium, zirconium, vanadium, chromium, manganese, cobalt, tungsten, molybdenum, platinum, aluminum, iron, steel, copper, nickel, silicon, germanium, indium phosphide, gallium arsenide, and their oxides, nitrides or alloys or mixtures, indium tin oxide, glassy carbon, sapphire, silicate glass and borate glass.
[0170] Embodiment 68: The use of any one of Embodiments 57 to 67, wherein the surface, preferably the surface of the biosensor, is modified by: polylysine, aminosilane, epoxysilane, nitrocellulose, carboxyl dextran, nanocarbon film, graphene oxide, carbon black and other carbon surfaces, carbon fibers, carbon plates, carbon cloth, activated carbon, glassy carbon, charcoal, activated charcoal, graphite powder, graphite fiber, carbon nanotubes, fullerene, carboxyl, azido, thiol, hydroxyl, epoxide, maleimide, alkyne, strained alkyne or any combination thereof.
[0171] Embodiment 69: The use of embodiment 68, wherein for the immobilization of the L-nucleic acid molecules of any one of embodiments 39 to 44, the surface is functionalized by: primary amines, thiols, azides, alkynes, olefins, tetrazines, tetrazoles or strained cycloalkynes, wherein preferably, the strained cycloalkynes are selected from the group comprising: dibenzocyclooctyl (DBCO), bicyclo[6.1.0]non-4-yne (BCN) or azadibenzocyclooctyne (ADIBO).
[0172] Embodiment 70: The use according to embodiment 69, wherein for the immobilization of the L-nucleic acid molecule according to any one of embodiments 42 to 43, a strain-promoted azide-alkyne cycloaddition reaction is used.
[0173] Embodiment 71: The use according to any one of embodiments 56 to 70, wherein the L-nucleic acid molecule according to any one of embodiments 44 to 46 is used for detection.
[0174] Embodiment 72: The use of any one of Embodiments 56 to 71, wherein the detection system of the biosensor is based on optical readout, mass change, refractive index, charge, surface stress and atomic force microscopy.
[0175] Embodiment 73: The use of Embodiment 72, wherein the detection system of the biosensor based on optical reading is fluorescence, absorption or luminescence.
[0176] Embodiment 74: The use described in Embodiment 72, wherein the detection system of the biosensor based on mass change is a quartz crystal microbalance or a micro-electromechanical system.
[0177] Embodiment 75: The use described in Embodiment 72, wherein the detection system of the biosensor based on refractive index is surface plasmon resonance, ring resonator or ellipsometry.
[0178] Embodiment 76: The use of Embodiment 72, wherein the charge-based detection system of the biosensor is electrochemical impedance, voltammetry, amperometry, potentiometry, conductivity, or field effect transistor.
[0179] Embodiment 77: The use described in Embodiment 72, wherein the detection system of the biosensor based on surface stress is a cantilever biosensor.
[0180] Embodiment 78: The use of any one of Embodiments 56 to 59, wherein CXCL8 is detected by a homogenous assay setting.
[0181] Embodiment 79: Use of the L-nucleic acid molecule according to any one of Embodiments 1 to 50 for detecting CXCL8, preferably human CXCL8.
[0182] Embodiment 80: The use of Embodiment 79, wherein CXCL8 is detected in a sandwich binding assay setting, a homologous assay setting, or a competition assay setting.
[0183] Embodiment 81: The use of Embodiment 80, wherein the sandwich binding assay setup, cognate assay setup or competition assay setup is suitable for directly or indirectly detecting CXCL8.
[0184] Embodiment 82: The use according to any one of Embodiments 78 to 81, wherein the L-nucleic acid molecule is covalently immobilized on the surface of a reaction vessel of a diagnostic agent, on the surface of a device in a reaction vessel of a diagnostic agent, or on the surface of a biosensor.
[0185] Embodiment 83: The use according to embodiment 82, wherein the L-nucleic acid molecule according to any one of embodiments 39 to 44 is used for immobilization.
[0186] Embodiment 84: The use of any one of Embodiments 82 to 83, wherein the surface, preferably the surface of the biosensor, is selected from the group consisting of gold, silver, titanium, zirconium, vanadium, chromium, manganese, cobalt, tungsten, molybdenum, platinum, aluminum, iron, steel, copper, nickel, silicon, germanium, indium phosphide, gallium arsenide, and their oxides, nitrides or alloys or mixtures, indium tin oxide, glassy carbon, sapphire, silicate glass and borate glass.
[0187] Embodiment 85: The use of any one of Embodiments 82 to 84, wherein the surface, preferably the surface of the biosensor, is modified by: polylysine, aminosilane, epoxysilane, nitrocellulose, carboxyl dextran, nanocarbon film, graphene oxide, carbon black and other carbon surfaces, carbon fibers, carbon plates, carbon cloth, activated carbon, glassy carbon, charcoal, activated charcoal, graphite powder, graphite fiber, carbon nanotubes, fullerene, carboxyl, azido, thiol, hydroxyl, epoxide, maleimide, alkyne, strained alkyne or any combination thereof.
[0188] Embodiment 86: The use of embodiment 85, wherein for the immobilization of the L-nucleic acid molecule of any one of embodiments 38 to 44, the surface is functionalized by: activated primary amines, thiol groups, azides or strained cycloalkynes, wherein preferably, the strained cycloalkynes are selected from the group comprising: dibenzocyclooctyl (DBCO), bicyclo[6.1.0]non-4-yne (BCN) or azadibenzocyclooctyne (ADIBO).
[0189] Embodiment 87: The use according to embodiment 86, wherein for the immobilization of the L-nucleic acid molecule according to any one of embodiments 42 to 43, a strain-promoted azide-alkyne cycloaddition reaction is used.
[0190] Embodiment 88: The use of any one of Embodiments 82 to 87, wherein the detection system of the biosensor is based on optical readout, mass change, refractive index, charge, surface stress and atomic force microscopy.
[0191] Embodiment 89: The use of Embodiment 88, wherein the detection system of the biosensor based on optical reading is fluorescence, absorption or luminescence.
[0192] Embodiment 90: The use described in Embodiment 85, wherein the detection system of the biosensor based on mass change is a quartz crystal microbalance system or a micro-electromechanical system.
[0193] Embodiment 91: The use of Embodiment 88, wherein the detection system of the refractive index based biosensor is surface plasmon resonance, ring resonator or ellipsometry.
[0194] Embodiment 92: The use of Embodiment 88, wherein the charge-based detection system of the biosensor is electrochemical impedance, voltammetry, amperometry, potentiometry, conductivity, or field effect transistor.
[0195] Embodiment 93: The use described in Embodiment 88, wherein the detection system of the biosensor based on surface stress is a cantilever biosensor.
[0196] Embodiment 94: The use according to any one of Embodiments 79 to 81, wherein the L-nucleic acid molecule comprises a modification group that allows detection of the L-nucleic acid molecule, preferably the modification group is a label.
[0197] Embodiment 95: The use of Embodiment 94, wherein the label is selected from the group comprising: biotin, bromodeoxyuridine, digoxigenin, oligonucleotides, fluorescent labels, electrochemiluminescent labels, radioactive labels, enzyme labels, UV labels, colloidal gold, nanoparticles and chelator molecule labels.
[0198] Embodiment 96: A kit for detecting CXCL8, wherein the kit comprises the L-nucleic acid molecule according to any one of embodiments 1 to 50, and at least instructions or a reaction container.
[0199] Embodiment 97: A method for detecting CXCL8 in a sample using an L-nucleic acid molecule as defined in any one of embodiments 1 to 50, wherein the method comprises the following steps:
[0200] a) providing a sample with an unknown concentration of CXCL8;
[0201] b) contacting the sample or a dilution thereof with a diagnostic agent, diagnostic means or biosensor as defined in any one of embodiments 56 to 78;
[0202] c) measuring a signal using a diagnostic agent, a diagnostic means or a biosensor as defined in any one of embodiments 56 to 78;
[0203] d) optionally, comparing the signal to a reference;
[0204] e) optionally, determining the CXCL8 concentration in the sample with unknown CXCL8 concentration by comparison with the signal obtained from at least one sample with known CXCL8 concentration, preferably said at least one sample with known CXCL8 concentration was subjected to steps b) to c).
[0205] Embodiment 98: A complex comprising the L-nucleic acid molecule of any one of embodiments 1 to 50 and CXCL8, wherein preferably the complex is a crystalline complex.
[0206] Embodiment 99: A method for screening an antagonist of activity mediated by CXCL8, comprising the following steps:
[0207] - providing candidate antagonists of activities mediated by CXCL8,
[0208] - providing an L-nucleic acid molecule as defined in any one of embodiments 1 to 50,
[0209] - providing an assay system that provides a signal in the presence of an antagonist of activity mediated by CXCL8, and
[0210] - Determining whether a candidate antagonist of activity mediated by CXCL8 is an antagonist of activity mediated by CXCL8.
[0211] Embodiment 100: A method for detecting an L-nucleic acid as defined in any one of embodiments 1 to 50 in a sample, wherein the method comprises the following steps:
[0212] a) providing a capture probe and a detection probe, wherein the capture probe is at least partially complementary to a first part of an L-nucleic acid molecule as defined in any one of embodiments 1 to 50, wherein the detection probe is at least partially complementary to a second part of an L-nucleic acid molecule as defined in any one of embodiments 1 to 50, or alternatively, the capture probe is at least partially complementary to a second part of an L-nucleic acid molecule as defined in any one of embodiments 1 to 50 and the detection probe is at least partially complementary to a first part of an L-nucleic acid molecule as defined in any one of embodiments 1 to 50;
[0213] b) adding the capture probe and the detection probe, separately or in combination, to a sample containing the L-nucleic acid molecule defined in any one of embodiments 1 to 50, or to a sample presumed to contain the L-nucleic acid molecule defined in any one of embodiments 1 to 50;
[0214] c) reacting the capture probe and the detection probe simultaneously or sequentially in any order with an L-nucleic acid molecule or a part thereof as defined in any one of embodiments 1 to 50;
[0215] d) optionally, detecting whether the capture probe provided in step a) hybridizes to an L-nucleic acid molecule as defined in any one of embodiments 1 to 50; and
[0216] e) detecting the complex formed in step c), said complex consisting of the L-nucleic acid molecule as defined in any one of embodiments 1 to 50 and said capture probe and said detection probe.
[0217] Embodiment 101: The method of Embodiment 100, wherein the detection probe comprises a detection means, and / or wherein the capture probe is fixed to a support, preferably a solid phase support.
[0218] Embodiment 102: The method of Embodiment 100 or 101, wherein any detection probe that is not part of the complex formed in step c) is removed from the reaction, so that only the detection probe that is part of the complex is detected in step e).
[0219] Embodiment 103: The method of any one of Embodiments 100 to 102, wherein step e) comprises the following steps: comparing the signal generated by the detection means when the capture probe and the detection probe are hybridized in the presence of the L-nucleic acid molecule or a portion thereof as defined in any one of Embodiments 1 to 50 and in the absence of the L-nucleic acid molecule as defined in any one of Embodiments 1 to 50.
[0220] Without wishing to be bound by any theory, the inventors have surprisingly found that the biostable L-nucleic acid molecules according to the present invention specifically bind to human CXCL8 with high affinity, thereby effectively inhibiting the binding of CXCL8 to its receptor. Unexpectedly, the nucleic acid molecules identified by the inventors specifically bind to and inhibit CXCL8, while not binding to and inhibiting the related chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL7, respectively, despite these proteins sharing structural features such as the ELR motif with CXCL8. The affinities in the picomolar range and the high selectivity exhibited by the CXCL8 binding nucleic acids were not foreseeable.
[0221] In particular, the inventors have surprisingly found that the nucleic acid molecules according to the invention are suitable for blocking the interaction of CXCL8 with its receptor and inhibiting chemotaxis induced by CXCL8, and the inhibition constant is in the picomolar range. In this regard, the nucleic acid molecules according to the invention can also be regarded as antagonists of the action of CXCL8, in particular as antagonists of the action of CXCL8 on its receptors CXCR1 and / or CXCR2. As preferably used herein, an antagonist of CXCL8 refers to a molecule that binds to CXCL8 (e.g., a nucleic acid molecule according to the invention) and inhibits the function of CXCL8 (preferably in the in vitro assay described in the examples or in the in vivo model).
[0222] Within the scope of the present invention, nucleic acid molecules according to the present invention are nucleic acids. In this case, the terms nucleic acid and nucleic acid molecules are used in a synonymous manner herein, unless otherwise indicated. Moreover, this type of nucleic acid (one or more) also preferably refers to nucleic acid molecules according to the present invention (one or more), nucleic acid (one or more) according to the present invention, nucleic acid (one or more) or nucleic acid molecules (one or more) according to the present invention in this article.
[0223] The feature of nucleic acid according to the present invention as described herein can be realized in any aspect of the present invention (comprising any embodiment thereof), wherein can use described nucleic acid individually or in any combination.Should be appreciated that any embodiment of an aspect in the present invention is also the embodiment of each and any other aspect.More specifically, any embodiment of the first aspect in the present invention is also the embodiment of any aspect in each and second aspect, third aspect, fourth aspect, fifth aspect, sixth aspect, seventh aspect, eighth aspect, ninth aspect, tenth aspect, eleventh aspect, twelfth aspect and thirteenth aspect.
[0224] With regard to the various diseases, conditions and disorders that can be treated or prevented using the nucleic acid molecules and compositions according to the invention, preferably pharmaceutical compositions comprising said nucleic acid molecules, it must be understood that such diseases, conditions and disorders are preferably those described herein, including and in particular those described and mentioned in the introductory part of the present application. In this regard, the various paragraphs of the specification and the introductory part of the specification form an integral part of the present invention to teach the suitability of the nucleic acid molecules of the invention for the prevention and treatment of said diseases, conditions and disorders, respectively. In addition, if the physiological effects of the CXCL8-CXCR1 receptor axis and the CXCL8-CXCR2 receptor axis are associated with higher plasma levels of CXCL8, then the nucleic acid molecules according to the invention are preferred.
[0225] As preferably used herein, the term CXCL8 refers to any CXCL8, including but not limited to mammalian CXCL8. Preferably, the mammalian CXCL8 is selected from the group comprising: human, monkey, rabbit, pig, dog, sheep, zebrafish and guinea pig CXCL8. More preferably, CXCL8 is human CXCL8, preferably having an amino acid sequence according to SEQ ID No 2.
[0226] As detailed in the claims and Example 1, the inventors were surprisingly able to identify a variety of different nucleic acid molecules capable of binding to human CXCL8.
[0227] As detailed herein, the inventors have identified a variety of different CXCL8 binding nucleic acid molecules capable of binding to human CXCL8, wherein the nucleic acid molecules can be characterized by nucleotide segments, which are also referred to as disclosed herein (see Example 1).
[0228] Each different type of CXCL8-binding nucleic acid molecule that binds to CXCL8 in the present invention comprises three different nucleotide segments: a first terminal nucleotide segment, a central nucleotide segment, and a second terminal nucleotide segment. Generally speaking, the CXCL8-binding nucleic acid molecule of the present invention comprises a terminal nucleotide segment at its 5' end and 3' end, i.e., a first terminal nucleotide segment and / or a second terminal nucleotide segment (also referred to as a 5'-terminal nucleotide segment and a 3'-terminal nucleotide segment, respectively). The first terminal nucleotide segment and the second terminal nucleotide segment can hybridize with each other (in principle due to their base complementarity), thereby forming a double-stranded structure when hybridized. However, under physiological conditions and / or non-physiological conditions, such hybridization is not necessarily achieved in the molecule. The three nucleotide segments of the CXCL8-binding nucleic acid molecule, i.e., the first terminal nucleotide segment, the central nucleotide segment, and the second terminal nucleotide segment, are arranged in the 5'→3' direction as: the first terminal nucleotide segment-central nucleotide segment-second terminal nucleotide segment. Alternatively, they are arranged in the 5'→3' direction as: the second terminal nucleotide segment, the central nucleotide segment, and the first terminal nucleotide segment.
[0229] The length of the central nucleotide segment of the nucleic acid according to the present invention is preferably 32 or 33 nucleotides.
[0230] According to the present invention, the length of the first terminal nucleotide segment of the nucleic acid is 3 to 6 nucleotides, preferably 5 to 6 nucleotides, and more preferably 5 nucleotides.
[0231] According to the present invention, the length of the second terminal nucleotide segment of the nucleic acid is 3 to 6 nucleotides, preferably 5 to 6 nucleotides, and more preferably 5 nucleotides.
[0232] If not indicated otherwise, the terms "segment" and "nucleotide segment" are used herein in a synonymous manner.
[0233] The sequence differences of the defined segments between different CXCL8 binding nucleic acid molecules can affect their binding affinity to CXCL8. Based on the binding analysis of different CXCL8 binding nucleic acid molecules of the present invention, the central segment and the nucleotides forming the central segment are individually and more preferably collectively essential for the binding of the CXCL8 binding nucleic acid molecule to CXCL8.
[0234] In a preferred embodiment, the nucleic acid molecule according to the invention is a single nucleic acid molecule. In a further embodiment, the single nucleic acid molecule exists as a plurality of single nucleic acid molecules, or exists as a plurality of species of single nucleic acid molecules.
[0235] It will be appreciated by the skilled person that a nucleic acid molecule according to the present invention preferably consists of nucleotides covalently linked to each other, preferably via phosphodiester linkages or phosphodiester bonds.
[0236] The nucleic acid molecule according to the present invention comprises two or more segments or one or more parts thereof, which can hybridize with each other in principle, and these contents are within the scope of the present invention. When this hybridization is performed, a double-stranded structure is formed. It will be understood by those skilled in the art that this hybridization may or may not occur, particularly under in vitro and / or in vivo conditions. Moreover, in the case of hybridization, this hybridization does not necessarily occur in the full length of the two segments, wherein, at least based on the principle of base pairing, this hybridization can occur in principle, thereby forming a double-stranded structure. As preferably used herein, a double-stranded structure is a part of a nucleic acid molecule, or a structure formed by two or more separate chains, or a structure formed by two spatially separated segments in a single strand of a nucleic acid molecule, wherein there is at least one base pair, preferably two or more base pairs, and its base pairing is preferably in accordance with the Watson-Crick (Watson-Crick) base pairing principle. It will also be understood by those skilled in the art that other base pairs such as Hoogsten base pairing may also be present in this double-stranded structure or form this double-stranded structure. It is also recognized that, whether such hybridization actually occurs in vivo and / or in vitro, the characteristics of the hybridization of the two segments preferably indicate that such hybridization is assumed to occur due to the base complementarity of the two segments. In conjunction with the present invention, these segments are the first terminal nucleotide segment and the second terminal nucleotide segment, which in one embodiment can hybridize as defined above.
[0237] In a preferred embodiment, the term arrangement as used herein refers to the order or sequence of the structural or functional features or elements described herein associated with the nucleotide molecules disclosed herein.
[0238] Nucleic acid molecules according to the present invention should also include nucleic acids that are substantially homologous to the specific sequences disclosed herein. The term substantially homologous should be understood as, for example, having a homology of at least 75%, preferably 85%, more preferably 90%, and most preferably higher than 95%, 96%, 97%, 98% or 99%.
[0239] The actual percentage of homologous nucleotides present in a nucleic acid molecule according to the invention will depend on the total number of nucleotides present in the nucleic acid molecule.The percentage of modification may be based on the total number of nucleotides present in the nucleic acid molecule.
[0240] The homology between two nucleic acid molecules can be determined in a manner known to those skilled in the art. More specifically, a sequence alignment algorithm can be used to calculate the sequence homology percentage of a test sequence (one or more) relative to a reference sequence based on specified program parameters. Preferably, the test sequence is a sequence or nucleic acid molecule that is said to be homologous to a different nucleic acid molecule, or it is necessary to test whether it is homologous to a different nucleic acid molecule, and if homologous, to what extent, wherein such different nucleic acid molecules are also referred to as reference sequences. In one embodiment, the reference sequence is a nucleic acid molecule as described herein, preferably a nucleic acid molecule having a sequence according to any one of SEQ.ID.No:14 to 26 and SEQ.ID.No:39 to 44 (preferably SEQ.ID.NO:16, SEQ.ID.NO:17, SEQ.ID.NO:25 and SEQ.ID.NO:26, SEQ.ID.NO:39, SEQ.ID.NO:40, SEQ.ID.NO:20 and SEQ.ID.No:41 to 44). Optimal sequence alignment can be performed for comparison by methods such as the local homology algorithm of Smith & Waterman (Smith & Waterman, 1981), the homology alignment algorithm of Needleman & Wunsch (Needleman & Wunsch, 1970), the similarity search method of Pearson & Lipman (Pearson & Lipman, 1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.) or by visual inspection.
[0241] An example of an algorithm suitable for determining percent sequence identity is the algorithm used in the Basic Local Alignment Search Tool (hereinafter referred to as "BLAST"), for example, see the article by Altschul et al. (Altschul et al., 1990 and Altschul et al., 1997). Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information (hereinafter referred to as "NCBI"). The default parameters used when determining sequence identity using software obtained from NCBI, such as BLASTN (for nucleotide sequences) and BLASTP (for amino acid sequences), are described in the article by McGinnis et al. (McGinnis et al., 2004).
[0242] Nucleic acid molecules according to the present invention should also include nucleic acid molecules with a certain degree of identity relative to the nucleic acid disclosed and described herein and defined by its nucleotide sequence. More preferably, the present invention also includes nucleic acid molecules with the following degree of identity relative to the nucleic acid disclosed and described herein and defined by its nucleotide sequence or its part: at least 75%, preferably 85%, more preferably 90% and most preferably higher than 95%, 96%, 97%, 98% or 99%.
[0243] The term nucleic acid of the present invention or nucleic acid molecule according to the present invention should also include nucleic acid molecules containing nucleic acid sequences disclosed or described herein or parts thereof, preferably to such an extent that the nucleic acid molecules or the parts thereof are involved in binding to human CXCL8. In one embodiment, such nucleic acid is one of the nucleic acid molecules described or disclosed herein, or a derivative and / or metabolite thereof, wherein such derivative and / or metabolite is preferably a truncated nucleic acid molecule compared to the nucleic acid molecules described or disclosed herein. Truncation may involve either or both ends of a nucleic acid molecule as disclosed or described herein. In addition, truncation may also involve an internal nucleotide sequence of the nucleic acid molecule, i.e., truncation may involve one or more nucleotides between the 5' terminal nucleotide and the 3' terminal nucleotide, respectively. Moreover, truncation should include deletions as few as a single nucleotide from the nucleic acid sequence disclosed herein. Truncation may also involve more than one segment in a nucleic acid described or disclosed herein, wherein the segment may be as short as one nucleotide long. A person skilled in the art may determine the binding of a nucleic acid molecule according to the present invention by using routine experiments or using or adopting a method as described herein, preferably as described in the Examples section herein.
[0244] The nucleic acid molecule according to the present invention can be a D-nucleic acid molecule or an L-nucleic acid molecule. Preferably, the nucleic acid molecule according to the present invention is an L-nucleic acid molecule.
[0245] It is also within the scope of the present invention that, in one embodiment, each and any of the nucleic acid molecules described herein are limited to the specific indicated nucleotide sequence(s) in terms of their nucleic acid sequence(s) and in their entirety. In other words, in such embodiments, the term "comprising" or "including" should be interpreted as meaning containing or consisting of.
[0246] It is also within the scope of the present invention that the nucleic acid molecule according to the present invention is part of a longer nucleic acid molecule, wherein the longer nucleic acid comprises several parts, wherein at least one such part is a nucleic acid according to the present invention or a part thereof. The other part or parts of such a longer nucleic acid molecule may be one or several D-nucleic acid molecules or one or several L-nucleic acid molecules. In the present invention, any combination may be used. These other part or parts of such a longer nucleic acid molecule, whether alone or in combination, in its entirety or in its specific combination, may exhibit a function different from binding, preferably a function different from binding to CXCL8. One possible function is to allow interaction with other molecules, wherein such other molecules are preferably different from CXCL8, such as, for example, for fixation, crosslinking, detection or amplification. In another embodiment of the present invention, the nucleic acid molecule according to the present invention, as individual or combined parts, comprises several nucleic acid molecules according to the present invention. Such nucleic acid molecules comprising several nucleic acids according to the present invention are also encompassed within the term longer nucleic acid.
[0247] As used herein, an L-nucleic acid is a nucleic acid or a nucleic acid molecule consisting of L-nucleotides, preferably consisting entirely of L-nucleotides.
[0248] As used herein, a D-nucleic acid is a nucleic acid or a nucleic acid molecule consisting of, preferably entirely consisting of, D-nucleotides.
[0249] Unless expressly stated to the contrary, the terms nucleic acid and nucleic acid molecule are used interchangeably herein.
[0250] Also, unless otherwise indicated, any nucleotide sequence is presented herein in a 5'→3' direction.
[0251] As preferably used herein, any nucleotide position is determined or referred to relative to the 5' end of the sequence, segment or subsegment containing such nucleotide. Accordingly, the second nucleotide is the second nucleotide counted from the 5' end of the sequence, segment or subsegment, respectively. Also according to this rule, the penultimate nucleotide is the second nucleotide counted from the 3' end of the sequence, segment or subsegment, respectively.
[0252] The nucleic acid molecule according to the present invention is composed of ribonucleotides, wherein
[0253] G is guanosine-5'-monophosphate,
[0254] C is cytidine 5'-monophosphate,
[0255] A is adenosine-5'-monophosphate,
[0256] U is uridine-5'-monophosphate.
[0257] To define ribonucleotide sequence motifs, the following IUPAC abbreviations for ambiguous nucleotides are used:
[0258] S strong G or C;
[0259] W weak A or U(T);
[0260] R purine G or A;
[0261] Y pyrimidine C or U (T);
[0262] K keto G or U (T);
[0263] M imino A or C;
[0264] B is not AC or U(T) or G;
[0265] D is not CA or G or U(T);
[0266] H is not GA or C or U(T);
[0267] V is not UA or C or G;
[0268] N all A or G or C or U (T)
[0269] For several reasons, it is advantageous to design the nucleic acid molecules of the present invention as L-nucleic acid molecules. L-nucleic acid molecules are enantiomers of naturally occurring nucleic acid molecules. However, due to the widespread presence of nucleases, D-nucleic acid molecules are less stable in aqueous solutions, and in particular in biological systems or biological samples. Naturally occurring nucleases, particularly nucleases from animal cells, cannot degrade L-nucleic acids. Because of this, the biological half-life of L-nucleic acid molecules is significantly increased in such biological systems including animals and humans. Since L-nucleic acid molecules lack degradability, no nuclease degradation products are produced, and no side effects resulting therefrom are seen in such biological systems including animals and humans. This aspect actually distinguishes L-nucleic acid molecules from all other compounds used for the treatment of diseases and / or disorders involving the presence of CXCL8. L-nucleic acid molecules that specifically bind to target molecules by a base pairing mechanism different from that of Watson Crick, or aptamers that are partially or completely composed of L-nucleotides, particularly aptamers having those aptamer portions that participate in the binding of aptamers to target molecules, are also referred to as spiegelmers. Aptamers and spiegelmers as such are known to the person skilled in the art and are described, among other similar substances, in "The Aptamer Handbook" (ed., Klussmann, 2006).
[0270] It is also within the scope of the present invention that the nucleic acid molecules of the present invention, whether present as D-nucleic acid molecules, L-nucleic acid molecules or D,L-nucleic acid molecules, can exist as single-stranded or double-stranded nucleic acid molecules. Generally speaking, the nucleic acid molecules are single-stranded nucleic acid molecules and exhibit a secondary structure defined by their primary sequence, and can also form a tertiary structure. However, the nucleic acid molecules can also be in double-stranded form, meaning that two strands that are complementary or partially complementary to each other hybridize with each other.
[0271] The nucleic acid molecules according to the invention may also be modified. Such modifications may involve individual nucleotides of the nucleic acid molecule, as is also well known to the person skilled in the art. Examples of such modifications are described by Venkatesan et al. (Venkatesan et al., 2003) and Kusser (Kusser, 2000) together with other modifications. Such modifications may be H atoms, F atoms or O-CH3 groups or NH2-groups at the 2' position of one or several nucleotides of all the individual nucleotides constituting the nucleic acid molecule. Furthermore, the nucleic acid molecule according to the invention may comprise at least one LNA nucleotide. In one embodiment, the nucleic acid molecule according to the invention consists of LNA nucleotides.
[0272] In one embodiment, the nucleic acid molecule according to the present invention can be a multi-component nucleic acid molecule. As used herein, a multi-component nucleic acid molecule is a nucleic acid molecule composed of at least two separate nucleic acid chains. These at least two nucleic acid chains form a functional unit, wherein this functional unit is a ligand of a target molecule, and preferably an antagonist of the target molecule, wherein the target molecule in the present case is CXCL8. The at least two nucleic acid chains described can be derived from any nucleic acid molecule of the present invention, which is derived in the following manner: cutting the nucleic acid molecule of the present invention to produce at least two chains, or synthesizing a nucleic acid molecule corresponding to the first part of the full-length nucleic acid molecule described in the present invention, and synthesizing another nucleic acid molecule corresponding to another part of the full-length nucleic acid molecule described in the present invention. According to the number of parts forming the full-length nucleic acid molecule, a corresponding number of parts with a desired nucleotide sequence will be synthesized. It should be understood that both the cutting method and the synthesis method can be used to produce a multi-component nucleic acid molecule, wherein there are more than two chains as exemplified above. In other words, the at least two separate nucleic acid chains are generally different from two chains that are complementary and hybridized to each other, although there may be a certain degree of complementarity between the at least two separate nucleic acid chains, and wherein this complementarity can cause hybridization of the separate chains.
[0273] Finally, the following contents are also within the scope of the present invention, achieving a completely closed structure of the nucleic acid molecule according to the present invention, i.e. a circular structure, that is, in one embodiment, the nucleic acid molecule according to the present invention is closed, preferably by covalent bonding, wherein more preferably, such covalent bonding occurs between the 5' end and the 3' end of the nucleic acid sequence of the nucleic acid molecule according to the present invention or any derivative thereof as disclosed herein.
[0274] One possibility to determine the binding constants of the nucleic acid molecules according to the invention is to use the method as described in Examples 3 and 4, which confirms the above findings that the nucleic acid molecules according to the invention show a favorable K D An appropriate measure intended to express the strength of binding between an individual nucleic acid molecule and its target (in this case CXCL8) is the so-called K D value, the K D The values themselves as well as methods for their determination are known to those skilled in the art.
[0275] Preferably, the nucleic acids according to the invention exhibit a K D The value is less than 1 μM. The K of about 1 μM D The K value can be said to be a characteristic of non-specific binding of nucleic acid to target. As is known to those skilled in the art, the K value of a group of compounds such as nucleic acid molecules according to the present invention is D The above K value of about 1 μM is within a certain range.D The K value is preferably D The upper limit of the target binding nucleic acid K D The lower limit of the value may be as low as about 10 pM or may be higher. It is within the scope of the present invention that the K of an individual nucleic acid binding to CXCL8 D The value is preferably within this range. By selecting any first value within this range and any second value within this range, a preferred range can be defined. The preferred upper limit K D The values are 250nM, 100nM and 20nM, and the preferred lower limit K D The values are 10 nM or less, 1 nM or less, 100 pM or less and 30 pM or less. A more preferred upper limit K D The value is 20 nM, and the more preferred lower limit K D The value is 30 pM or less.
[0276] In addition to the binding properties of the nucleic acid molecules according to the present invention, the nucleic acid molecules according to the present invention inhibit the function of the corresponding target molecule (in the present case, CXCL8). The inhibition of CXCL8 function (such as the stimulation of the corresponding receptor described above) is achieved by combining the nucleic acid molecules according to the present invention with CXCL8 and forming a complex of the nucleic acid molecules according to the present invention and CXCL8. This complex of nucleic acid molecules and CXCL8 cannot stimulate the receptors stimulated by CXCL8 under normal circumstances, that is, the receptors stimulated when CXCL8 is not present in the complex with the nucleic acid molecules of the present invention. Therefore, the inhibition of receptor function by the nucleic acid molecules according to the present invention does not depend on the corresponding receptors that can be stimulated by CXCL8, but is caused by the nucleic acid molecules according to the present invention preventing CXCL8 from stimulating the receptor.
[0277] One possibility to determine the inhibition constant of the nucleic acid molecules according to the invention is to use the method as described in Example 5, which confirms the above findings that the nucleic acid molecules according to the invention show a favorable inhibition constant, allowing the use of the nucleic acids in therapeutic treatment regimens. A suitable measure intended to express the strength of the inhibitory effect of an individual nucleic acid molecule on the interaction between the target (in the present case CXCL8) and its corresponding receptor is the so-called half maximal inhibitory concentration (abbreviated as IC 50 ), shown in IC 50 And its determination method are known to those skilled in the art.
[0278] Preferably, the nucleic acid molecules according to the present invention exhibit an IC 50 The value is less than 1 μM. The IC value is about 1 μM 50 The IC value can be said to be a characteristic of the non-specific inhibition of the target function by the nucleic acid molecule. As is known to those skilled in the art, the IC value of a group of compounds such as nucleic acid molecules according to the present invention is50 The above IC value of about 1 μM is within a certain range. 50 value is preferably the IC 50 The IC value of the target binding nucleic acid molecule 50 The lower limit of the value may be as low as about 10 pM or may be higher. It is within the scope of the present invention that the IC value of an individual nucleic acid binding to CXCL8 50 The value is preferably within this range. By selecting any first value within this range and any second value within this range, a preferred range can be defined. Preferred upper limit IC 50 The values are 250nM, 100nM and 20nM, with the preferred lower limit IC 50 The values are 10 nM or less, 1 nM or less, 500 pM or less and 260 pM or less. More preferred upper limit IC 50 The value is 20nM, and the more preferred lower limit IC 50 The value is 260pM or less.
[0279] Nucleic acid molecules according to the present invention can have any length, provided that they are still able to bind target molecules.It should be understood in the art that there is a preferred length according to nucleic acid molecules according to the present invention.Usually, the length is 15 to 120 nucleotides.Those skilled in the art will appreciate that, for nucleic acid molecules according to the present invention, any integer from 15 to 120 is a possible length.More preferably, the length range of nucleic acid molecules according to the present invention is as follows: about 20 to 100 nucleotides, about 20 to 80 nucleotides, about 20 to 60 nucleotides, about 38 to 45 nucleotides and about 40 to 45 nucleotides.
[0280] It is within the scope of the present invention that the nucleic acid molecules of the present invention include such parts, which are preferably high molecular weight parts and / or which are preferably features that allow modification of the residence time of the nucleic acid molecules in an animal body (preferably human body), etc. A particularly preferred embodiment of this type of modification is to carry out PEGylation and HESization to the nucleic acid molecules according to the present invention. As used herein, PEG represents polyethylene glycol, and HES represents hydroxyethyl starch. As preferably used herein, PEGylation is to modify the nucleic acid molecules according to the present invention, wherein this modification is composed of the PEG part attached to the nucleic acid molecules according to the present invention. As preferably used herein, HESization is to modify the nucleic acid molecules according to the present invention, wherein this modification is composed of the HES part attached to the nucleic acid molecules according to the present invention. These modifications and methods for modifying nucleic acid molecules using these modifications are described in patent applications EP 1306382 and WO2018099600A1, and their disclosures are fully incorporated herein by reference.
[0281] In the case of PEG as such a high molecular weight portion, the molecular weight is preferably about 20,000 to about 120,000 Da, more preferably about 30,000 to about 80,000 Da, and most preferably about 40,000 Da. In another preferred embodiment, the PEG is a PEG as described in International Patent Application WO03076490. In the case of HES as such a high molecular weight portion, the molecular weight is preferably about 50 kDa to about 1000 kDa, more preferably about 100 kDa to about 700 kDa, and most preferably 200 kDa to 500 kDa. HES exhibits a molar substitution of 0.1 to 1.5, more preferably 1 to 1.5, and exhibits a substitution of about 0.1 to 15, preferably about 3 to 10, expressed as a C2 / C6 ratio. Methods for HES modification are described, for example, in German Patent Application DE 12004 006 249.8, the disclosure of which is incorporated herein by reference in its entirety.
[0282] In principle, such modification can be performed at any position of the nucleic acid molecule of the present invention. Preferably, such modification is performed at the 5'-terminal nucleotide, the 3'-terminal nucleotide and / or at any nucleotide between the 5' nucleotide and the 3' nucleotide of the nucleic acid molecule.
[0283] Modification and preferred PEG and / or HES part can be attached to nucleic acid molecules of the present invention directly or indirectly, preferably by the indirect way of joint.Also within the scope of the present invention, nucleic acid molecules according to the present invention comprise one or more modifications, preferably one or more PEG parts and / or HES parts.In one embodiment, individual joint molecule is attached to nucleic acid molecules according to the present invention by more than one PEG part or HES part.Joint used in the present invention itself can be linear or branched.This joint is known to those skilled in the art, and it is further described in International Patent Application WO2005 / 074993 and WO2003 / 035665.
[0284] In a preferred embodiment, the joint is a biodegradable joint. The biodegradable joint allows the characteristics of the residence time of the nucleic acid molecules according to the present invention in the animal body (preferably the human body) to be changed, which is due to the release modification from the nucleic acid molecules according to the present invention. The use of a biodegradable joint can allow better control of the residence time of the nucleic acid molecules according to the present invention. The preferred embodiment of this type of biodegradable joint is a biodegradable joint as described in, but not limited to, international patent applications WO2006 / 052790, WO2008 / 034122, WO2004 / 092191 and WO2005 / 099768.
[0285] It is within the scope of the present invention that the modification or modifying group is a biodegradable modification, wherein the biodegradable modification can be attached directly or indirectly to the nucleic acid molecule of the present invention, preferably through a joint. The biodegradable joint allows the characteristics of the nucleic acid molecule according to the present invention in terms of residence time in an animal (preferably in the human body) to be changed, due to release or degradation modification from the nucleic acid molecule according to the present invention. The use of a biodegradable joint allows for better control of the residence time of the nucleic acid molecule according to the present invention. Preferred embodiments of such biodegradable modifications are biodegradable modifications as described in, but not limited to, international patent applications WO2002 / 065963, WO2003 / 070823, WO2004 / 113394 and WO2000 / 41647, preferably on page 18, lines 4 to 24 of WO2000 / 41647.
[0286] In another preferred embodiment, the linker has the following structure:
[0287]
[0288] For example, corresponding linkers are disclosed by international patent application WO 2015 / 062743. As indicated by the above structures, the linker connects two separate PEG moieties to the OH groups in the phosphate part of the nucleotides in the nucleic acid molecule according to the invention.
[0289] In addition to the modifications described above, other modifications may also be used to change the characteristics of the nucleic acid molecules according to the present invention, wherein such other modifications may be selected from the group consisting of proteins, lipids (e.g. cholesterol) and sugar chains (e.g. amylase, dextran, etc.).
[0290] Without wishing to be bound by any theory, by modifying the nucleic acid molecules according to the present invention with a high molecular weight portion such as a polymer, more specifically one or more polymers disclosed herein (which are preferably physiologically acceptable), the excretion kinetics of the modified nucleic acid molecules of the present invention from the animal body or human body to which the modified nucleic acid molecules of the present invention are administered are changed. More specifically, due to the increase in the molecular weight of the modified nucleic acid molecules according to the present invention and due to the fact that the nucleic acid molecules according to the present invention do not enter metabolism (especially when they are in the L configuration, i.e. as L-nucleic acid molecules), excretion from the animal body, preferably from the mammalian body, more preferably from the human body is reduced. Excretion is usually carried out through the kidneys, so the inventors speculate that the glomerular filtration rate of the modified nucleic acid molecules is significantly reduced compared to nucleic acid molecules without such high molecular weight modifications, which results in a prolonged residence time of the modified nucleic acid molecules in the animal body. In this regard, it is particularly noteworthy that despite such high molecular weight modifications, the specificity of the nucleic acid molecules according to the present invention is not affected in an unfavorable manner. In addition to other features, the nucleic acid molecules according to the present invention have surprising features (usually not expected from pharmaceutically active compounds), and it is not necessary to provide a sustained release pharmaceutical formulation in order to provide a sustained release for the nucleic acid molecules according to the present invention. More precisely, the nucleic acid molecules according to the present invention, in their modified form containing a high molecular weight portion, can already be used as sustained release formulations themselves, and it is precisely because of the modification that they already act like being released from a sustained release formulation. In this regard, such modifications (one or more) of the nucleic acid molecules according to the present invention as disclosed herein and the nucleic acid molecules according to the present invention modified therefrom and any composition comprising them can provide unique, preferably controllable pharmacokinetics and their biodistribution. This also includes the residence time in the animal body and human circulation and the distribution in the tissues of such animals and humans. Such modifications are further described in patent application WO2003 / 035665.
[0291] However, it is also within the scope of the present invention that nucleic acid molecules according to the present invention do not comprise any modification, and especially do not comprise high molecular weight modifications such as PEG or HES. When nucleic acid molecules according to the present invention show preferential distribution to any target organ or target tissue in the body, or when it is desired to quickly remove nucleic acid molecules according to the present invention from the body after administration, this type of embodiment is particularly preferred. Nucleic acid molecules according to the present invention as disclosed herein with preferential distribution characteristics to any target organ or target tissue in the body allow to establish effective local concentrations in the target tissue, while maintaining low systemic concentrations of nucleic acid molecules. So low doses can be used, which is not only beneficial from an economic point of view, but also reduces the unnecessary exposure of other tissues to the nucleic acid molecules, thereby reducing potential side effects. In the case of using nucleic acid molecules according to the present invention or medicaments comprising it for in vivo imaging or requiring specific treatment administration, it may be desirable to quickly remove nucleic acid molecules according to the present invention etc. from the body after administration.
[0292] The nucleic acids of the present invention (also referred to herein as nucleic acids according to the present invention or nucleic acid molecules according to the present invention) and / or the antagonists according to the present invention can be used to produce or prepare medicaments. Such medicaments or pharmaceutical compositions according to the present invention comprise at least one nucleic acid of the present invention, optionally together with other pharmaceutically active compounds, wherein the nucleic acids of the present invention themselves are preferably used as pharmaceutically active compounds. In a preferred embodiment, such medicaments contain at least a pharmaceutically acceptable carrier. For example, such carriers can be water, buffer, PBS, glucose solution (preferably 5% glucose balanced salt solution), starch, sucrose, gelatin or any other acceptable carrier material. Such carriers are generally known to those skilled in the art. Those skilled in the art will recognize that any embodiment, use and aspect of the medicament of the present invention or any embodiment, use and aspect related thereto are also applicable to the pharmaceutical composition of the present invention and the nucleic acid molecule of the present invention, and vice versa, the pharmaceutical composition and nucleic acid molecule are used to treat and / or prevent and / or diagnose any disease disclosed or described herein.
[0293] The indications, diseases and conditions to be treated and / or prevented by the nucleic acids, pharmaceutical compositions and medicaments according to the invention or prepared according to the invention are caused by the direct or indirect involvement of CXCL8 in the corresponding pathogenesis.
[0294] CXCL8 (UniProtKB / Swiss-Prot P10145, IL8_HUMAN; SEQ ID NO: 2), also known as interleukin 8 (IL-8), neutrophil-activating protein 1 (NAP-1), monocyte-derived neutrophil chemoattractant factor (MDNCF) or granulocyte chemoattractant protein 1 (GCP-1), is a small basic protein belonging to the CXC chemokine subfamily, which has pro-inflammatory and pro-angiogenic properties and is characterized by a glutamic acid-leucine-arginine (ELR) motif at the N-terminus. The ELR-positive chemokines CXCL1 (also known as growth-regulated alpha protein, Gro-α, melanoma growth-stimulating activity protein, MGSA or NAP-3), CXCL2 (also known as Gro-β or macrophage inflammatory protein 2-α, MIP2-α), CXCL3 (also known as Gro-γ or MIP2-β), CXCL5 (also known as epithelial cell-derived neutrophil-activating protein 78, ENA-78 or small inducing cytokine B5), CXCL6 (also known as chemokine α3, CKA-3, granulocyte chemoattractant protein 2, GCP-2 or small inducing cytokine B6), CXCL7 (also known as platelet basic protein, PBP, leukocyte-derived growth factor, LDGF, macrophage-derived growth factor, MDGF or small inducing cytokine B7) and CXCL8 are all agonists of the receptor CXCR2 (also known as IL8RB, type 2 IL8R, CD182, CDw128b or GRO / MGSA receptor). CXCL6, CXCL7, and CXCL8 are agonists of the receptor CXCR1 (also known as IL8RA, type 1 IL8R, CD181, or CDw128a). CXCL8 binds to the receptor CXCR1 and the receptor CXCR2 with similar affinity, about 4 nM. Binding of CXCL8 to CXCR1 / 2 triggers Gαi-dependent signaling pathways and, for example, induces neutrophil migration, degranulation, and oxidative burst. Phosphorylation, β-arrestin recruitment, and receptor internalization can modulate receptor sensitivity (Ha, Theranostics 2017). CXCL7 and CXCL8 have the highest homology, with 33 identical amino acids. CXCL8 from non-human primates (wild-caught rhesus macaques, cynomolgus monkeys) shares 95% identity with human CXCL8 (73 of 77 amino acids are identical). Orthologs of CXCL8 are not present in mice and rats.
[0295] Of course, since the CXCL8 binding nucleic acid molecules according to the present invention interact with or bind to CXCL8, the skilled artisan will generally understand that the CXCL8 binding nucleic acid molecules according to the present invention can be readily used to treat, prevent and / or diagnose any human and animal diseases as described herein. In this regard, it should be recognized that the nucleic acid molecules according to the present invention can be used to treat and / or prevent any disease, disorder or condition described herein, regardless of the underlying mode of action of such disease, disorder and condition.
[0296] Without wishing to be bound by any theory, the rationale for the use of nucleic acid molecules according to the present invention in connection with a variety of diseases, disorders and conditions is provided below, thereby justifying the claimed therapeutic, prophylactic and diagnostic applicability of nucleic acid molecules according to the present invention. In order to avoid any unnecessary repetition, it should be recognized that due to the involvement of the CXCL8-CXCL8 receptor axis as listed in connection therewith, the axis can be addressed by the nucleic acid molecules according to the present invention to achieve the claimed therapeutic, prophylactic and diagnostic effects. It should also be recognized that the specific circumstances of the patient's disease, disorder and condition and any details of the described treatment regimen in connection therewith can be addressed by the preferred embodiments of the present application.
[0297] CXCL8 and its receptors are involved in or participate in the pathophysiological processes of a variety of inflammatory diseases, and the potential of inhibiting CXCL8 for treating such inflammatory diseases is supported by animal disease models. Inflammatory diseases and / or disorders and / or conditions that can be treated and / or prevented using the medicament according to the present invention include, but are not limited to, the following:
[0298] Inflammatory diseases of the respiratory system
[0299] a. Chronic obstructive pulmonary disease
[0300] b. Acute respiratory distress syndrome
[0301] c. Asthma and allergic inflammation
[0302] d. Bronchitis, bronchiolitis, bronchiolitis obliterans, bronchiectasis
[0303] e. Interstitial lung disease including pulmonary fibrosis
[0304] f. Cystic fibrosis
[0305] g. Lung transplantation
[0306] h. Lung damage caused by physical injury, such as cigarette smoke, callaps
[0307] Re-extension, hyperoxia
[0308] i. Lung damage caused by bacterial, viral or fungal infection (pneumonia)
[0309] Inflammatory diseases of the skin
[0310] a. Neutrophilic dermatosis
[0311] b. Psoriasis
[0312] c. Bullous pemphigoid
[0313] d. Epidermolysis bullosa
[0314] e. Hidradenitis suppurativa
[0315] f. Neurodermatitis
[0316] g. Eczema
[0317] Autoimmune diseases
[0318] a. Inflammatory bowel disease
[0319] b. Ulcerative colitis
[0320] c. Multiple sclerosis
[0321] d. Rheumatoid arthritis
[0322] e. Type 1 diabetes
[0323] f. Ankylosing spondylitis
[0324] Neurological diseases
[0325] a. Neurosweetness
[0326] b. Alzheimer's disease
[0327] Ischemia-reperfusion injury
[0328] a. Stroke
[0329] b. Myocardial infarction
[0330] c. Cerebral ischemia and cerebral infarction
[0331] Other inflammatory diseases
[0332] a. Atherosclerosis
[0333] b. Islet transplant rejection
[0334] c. Organ transplant rejection and / or delayed function
[0335] d. Spinal cord injury
[0336] e. Cystitis
[0337] (Reviewed by Russo, Expert Rev Clin Immunol 2014 and Ha, Theranostics 2017).
[0338] CXCL8 is overexpressed in human cancers, and the potential for inhibiting CXCL8 for treating cancer is supported by experimental cancer models. Accordingly, diseases and / or disorders and / or conditions that can be treated and / or prevented using the agents according to the present invention include, but are not limited to, the following:
[0339] a. Lung cancer
[0340] b. Colon cancer
[0341] c. Colorectal cancer
[0342] d. Prostate cancer, including hormone-refractory prostate cancer
[0343] e. Pancreatic cancer
[0344] f. Liver cancer
[0345] g.Breast cancer
[0346] h. Ovarian cancer
[0347] i. Thyroid cancer
[0348] j. Melanoma
[0349] k. Glioblastoma
[0350] 1. Osteosarcoma
[0351] m.Esophageal cancer
[0352] n.Hematological cancers (leukemia and lymphoma)
[0353] o. PTEN-deficient tumors
[0354] Tumors with p.P53 mutation
[0355] q. Kras mutant tumors
[0356] r. Treatment-resistant cancers, including cancers resistant to treatment with chemotherapeutic agents, anti-angiogenic agents, tyrosine kinase inhibitors, and immune checkpoint inhibitors.
[0357] In a further embodiment, the medicament comprises an additional pharmaceutically active agent for treating cancer and / or tumors. Such additional pharmaceutically active compounds are, but are not limited to, known anti-tumor active substances such as alkylating agents, antimetabolites, anti-angiogenic agents, mitotic inhibitors, topoisomerase inhibitors, cell signal transduction inhibitors, hormones, antibodies, immunoconjugates and fusion proteins, etc.
[0358] Additional pharmaceutically active compounds for the treatment of cancer and / or tumors are immunotherapeutic agents. Such additional pharmaceutically active compounds are, but are not limited to, checkpoint inhibitors, cancer vaccines, immunostimulants, cellular cancer therapies, and the like.
[0359] Other pharmaceutically active compounds are known, including but not limited to the following: thymidylate synthase inhibitors such as bleomycin, Raltitrexed and Pemetrexed, enzymes such as L-asparaginase, proteasome inhibitors such as Miltefosin and ANAgrelid, Bortezomib.
[0360] It is within the scope of the present invention that medicaments and pharmaceutical compositions, respectively, containing the nucleic acids according to the invention can be used in therapy in this way.
[0361] In another embodiment, the medicament comprises other pharmaceutically active agents for treating inflammatory diseases. Such other pharmaceutically active compounds are, but are not limited to, substances known to suppress the immune system, such as nonsteroidal anti-inflammatory drugs, corticosteroids, calcineurin inhibitors, cyclosporin A, methotrexate, azathioprine, tacrolimus, rapamycin, chlorambucil, leflunomide, mycophenolate mofetil, brequinar, mizoribine, thalidomide, deoxyspergualin, dapsone, hydroxychloroquine, sulfasalazine, antihistamines, or anti-inflammatory biological agents such as anti-tumor necrosis factor antibody adalimumab, B cell depleting anti-CD20 antibody rituximab, anti-IL6R antibody tocilizumab, anti-IgE antibody omalizumab and intravenous immunoglobulin, etc.
[0362] Finally, the other pharmaceutically active agent may be any other modulator of chemokine activity, which may be an agonist or antagonist of a chemokine or an agonist or antagonist of a chemokine receptor. Alternatively or additionally, such another pharmaceutically active agent is another nucleic acid molecule according to the invention. Alternatively, the medicament comprises at least one further nucleic acid that binds to a target molecule other than CXCL8 or exhibits a function different from one of the nucleic acids according to the invention.
[0363] It is within the scope of the present invention that the medicament is in principle used alternatively or additionally for the prevention of any disease disclosed in terms of the use of the medicament for the treatment of the disease. Accordingly, corresponding markers, i.e. corresponding markers for corresponding diseases, are known to the person skilled in the art. Preferably, the corresponding marker is CXCL8.
[0364] In one embodiment of the agents of the present invention, such agents are used in combination with other treatments for any of the diseases disclosed herein, particularly those diseases for which the agents of the present invention are to be used.
[0365] "Combination therapy" (or "co-therapy") includes administering a drug of the present invention and at least one second agent as part of a specific treatment regimen in order to provide a beneficial effect from the combined action of these therapeutic agents (i.e., the drug of the present invention and the second agent). The beneficial effects of this combination include, but are not limited to, pharmacokinetic or pharmacodynamic co-actions brought about by the combination of therapeutic agents. The combined administration of these therapeutic agents is usually carried out within a limited period of time (generally minutes, hours, days or weeks, depending on the combination selected).
[0366] "Combination therapy" may (but generally does not) encompass the administration of two or more of these therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in the combination of the present invention. "Combination therapy" is intended to include the administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at different times, as well as the administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner. For example, substantially simultaneous administration may be accomplished by administering to a subject a single capsule of each therapeutic agent in a fixed ratio, or by administering to a subject a plurality of single capsules of each therapeutic agent.
[0367] Sequential or substantially simultaneous administration of each therapeutic agent can be performed by any suitable route, including but not limited to topical routes, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucosal tissues. The therapeutic agents can be administered by the same route or by different routes. For example, the first therapeutic agent in a selected combination can be administered by injection, while the other therapeutic agents in the combination can be administered topically.
[0368] Alternatively, for example, all therapeutic agents can be applied topically or all therapeutic agents can be applied by injection. Unless otherwise indicated, the order of application of the therapeutic agents is not strictly limited. "Combination therapy" can also include further application of the therapeutic agents as described above in combination with other biologically active ingredients. In the case where the combination therapy also includes non-drug therapy, this non-drug therapy can be performed at any appropriate time, as long as a beneficial effect is obtained in the combined effect of the therapeutic agent and the non-drug therapy. For example, in appropriate circumstances, when this non-drug therapy is temporarily (possibly for several days or even weeks) removed from the application of the therapeutic agent, a beneficial effect can still be obtained.
[0369] As listed in the general terms above, the medicine according to the present invention can be used in principle in any form known to those skilled in the art. The preferred route of administration is systemic administration, more preferably by parenteral administration, preferably by injection. Alternatively, the medicine can be applied topically. Other routes of administration include intramuscular, intraperitoneal and subcutaneous, oral, intranasal, intratracheal or pulmonary administration, wherein the route of administration with minimal invasiveness and simultaneously ensuring effectiveness is preferred.
[0370] Commonly used parenteral administrations are subcutaneous, intramuscular or intravenous injection and infusion. In addition, one mode of parenteral administration employs the implantation of a slow release or sustained release system to ensure that a constant dosage level is maintained, which is well known to those skilled in the art.
[0371] Further, the preferred medicament of the present invention can be applied in the form of intranasal administration by topical application of suitable intranasal vehicles, inhalants, or by transdermal administration using the form of transdermal patches well known to those skilled in the art. In order to be applied in the form of a transdermal delivery system, during the entire dosage regimen, the administration of the dosage will certainly be continuous rather than intermittent. Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of the active ingredient is usually 0.01% to 15%, w / w or w / v scope.
[0372] The medicament of the present invention will usually contain an effective amount of active ingredient (one or more) of the therapy, including but not limited to the nucleic acid molecules of the present invention dissolved in or dispersed in a pharmaceutically acceptable medium. Pharmaceutically acceptable media or carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delay agents, etc. It is well known in the art to use such media and agents for pharmaceutically active substances. Supplementary active ingredients can also be incorporated into the medicament of the present invention.
[0373] On the other hand, the present invention relates to pharmaceutical compositions. Such pharmaceutical compositions comprise at least one nucleic acid according to the present invention and preferably comprise a pharmaceutically acceptable vehicle. Such vehicles may be any vehicle or any adhesive used and / or known in the art. More specifically, such adhesives or vehicles are any adhesives or vehicles discussed in connection with the preparation of the medicament disclosed herein. In another embodiment, the pharmaceutical composition comprises an additional pharmaceutically active agent.
[0374] The preparation of medicaments and pharmaceutical compositions will be known to those skilled in the art with reference to the present disclosure. Generally speaking, such compositions can be prepared as injections in the form of liquid solutions or suspensions; solid forms suitable for dissolution or suspension in liquids prior to injection; tablets or other solids suitable for oral administration; prepared as time-release capsules; or prepared in any other form currently used, including eye drops, creams, lotions, oils, inhalants, etc. It may also be particularly useful for surgeons, physicians, or health care workers to use sterile preparations such as saline-based lotions to treat special areas in the surgical field. The composition can also be delivered via microdevices, microparticles, or sponges.
[0375] Once formulated, the agent or pharmaceutical composition will be administered in a manner compatible with the dosage formulation and in a pharmacologically effective amount. The formulations are conveniently administered in a variety of dosage forms, such as the type of injectable solutions described above, but may also employ drug release capsules and the like.
[0376] In this case, the amount of active ingredient and the volume of the composition to be administered will depend on the individual or subject to be treated. The specific amount of active compound required for administration depends on the judgment of the practitioner and is unique to each individual.
[0377] The smallest volume of the medicament or pharmaceutical composition necessary to disperse the active compound is generally used. Suitable administration schedules are also variable but typically represent an initial administration of the compound and monitoring of the results, followed by further controlled doses at subsequent time intervals.
[0378] For example, for oral administration in the form of tablets or capsules (e.g., gelatin capsules), the active drug component (i.e., the nucleic acid molecules of the present invention and / or any additional pharmaceutically active agent, also referred to herein as therapeutic agent(s) or active compound(s)) can be combined with an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. Moreover, when necessary or necessary, suitable binders, lubricants, disintegrants, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch slurry, gelatin, methylcellulose, sodium carboxymethylcellulose, and / or polyvinyl pyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as gum arabic, tragacanth, or sodium alginate, etc., polyethylene glycol, wax, etc. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talc, stearic acid, its magnesium salt or calcium salt, and / or polyethylene glycol, etc. Disintegrators include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum starch, alginic acid and its sodium salt or effervescent mixture, etc. For example, diluents include lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine.
[0379] The pharmaceutical agent or composition of the present invention may also be administered in such oral dosage forms as timed-release and sustained-release tablets or capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. Suppositories are advantageously prepared from fatty emulsions or suspensions.
[0380] The pharmaceutical compositions or medicaments may be sterilized and / or contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, dissolution promoters, salts for regulating osmotic pressure and / or buffers. In addition, they may contain other substances of therapeutic value. The compositions are prepared according to conventional mixing, granulation or coating methods and usually contain about 0.1% to 75% of active ingredient, preferably about 1% to 50%.
[0381] For example, liquid compositions, especially injectable compositions, can be prepared by dissolution, dispersion, etc. The active compound is dissolved in a pharmaceutically pure solvent such as water, saline, dextrose aqueous solution, glycerol, ethanol, or mixed therewith to form an injectable solution or suspension. In addition, a solid form suitable for dissolution in a liquid before injection can be prepared.
[0382] For solid compositions, excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, etc. The active compounds defined above can also be formulated into suppositories, for example using polyalkylene glycols such as propylene glycol as carriers. In some embodiments, suppositories are advantageously prepared from fatty emulsions or suspensions.
[0383] The medicaments, pharmaceutical compositions and nucleic acid molecules described in the present invention can also be administered in the form of liposome delivery systems such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles, respectively. Liposomes can be formed from a variety of phospholipids containing cholesterol, stearylamine or phosphatidylcholine. In some embodiments, the membrane of the lipid component is hydrated with an aqueous drug solution to form a lipid layer that encapsulates the drug, which is well known to those skilled in the art. For example, the nucleic acid molecules described herein can be provided in a manner that constructs a complex with a lipophilic compound or a non-immunogenic high molecular weight compound, and the methods used to construct such a complex are known in the art. In addition, liposomes can carry such nucleic acid molecules on their surface for targeting and carry cytotoxic agents inside them, thereby mediating cell killing. Examples of nucleic acid-associated complexes are provided in U.S. Patent No. 6,011,020.
[0384] The medicament, pharmaceutical composition and nucleic acid molecule of the present invention can also be coupled with soluble polymers used as targetable drug carriers, respectively. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethylaspanamidephenol or polyethylene oxide polylysine substituted with palmitoyl residues. Moreover, the medicament and nucleic acid molecule of the present invention can be coupled to a class of biodegradable polymers for realizing controlled drug release, such as crosslinking or amphiphilic block copolymers of polylactic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyran, polycyanoacrylate and hydrogel, respectively.
[0385] When necessary, the pharmaceutical compositions and medicaments to be administered may also contain small amounts of non-toxic auxiliary substances, such as wetting agents or emulsifiers, pH buffering agents, and other substances such as sodium acetate and triethanolamine oleate, respectively.
[0386] The dosage regimen using the nucleic acid molecules, agents or pharmaceutical compositions of the present invention is selected based on a variety of factors, including the type, race, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the patient's renal and liver function; and the specific aptamer or salt thereof used. An ordinary physician or veterinarian can easily determine and prescribe the effective amount of the drug required to prevent, counteract or arrest the progression of the condition.
[0387] In treating any of the diseases disclosed herein, effective plasma levels of nucleic acids according to the present invention preferably range from 500 fM to 500 μM.
[0388] The nucleic acid molecules, medicaments and pharmaceutical compositions according to the present invention can be administered preferably in one dose per day, every two or three days, every week, every two weeks, every month or every three months, respectively.
[0389] It is within the scope of the present invention that the agents as described herein constitute the pharmaceutical compositions disclosed herein.
[0390] On the other hand, the present invention relates to a method for treating a patient in need of such treatment, wherein the method comprises administering a pharmaceutically active amount of at least one nucleic acid molecule according to the present invention. In one embodiment, the subject suffers from a disease or is at risk of developing such a disease, wherein the disease is any disease disclosed herein, in particular any disease disclosed in connection with the use of any nucleic acid according to the present invention for the preparation of a medicament.
[0391] It should be understood that the nucleic acids and antagonists according to the invention can be used not only as medicaments or for the preparation of medicaments, but also for cosmetic purposes, in particular with regard to inflamed regional skin lesions in which CXCL8 is involved. Therefore, another condition or disease that can be treated or prevented using the nucleic acids, medicaments and / or pharmaceutical compositions according to the invention is inflamed regional skin lesions.
[0392] Of course, since the CXCL8-binding nucleic acid molecules according to the present invention interact with or bind to human CXCL8, technicians generally understand that the CXCL8-binding nucleic acid molecules according to the present invention can be easily used to detect CXCL8 and to prepare diagnostic agents or biosensors.
[0393] As preferably used herein, the diagnostic agent, diagnostic reagent or diagnostic means or biosensor is suitable for directly or indirectly detecting CXCL8, preferably CXCL8 as described herein, and more preferably CXCL8 as described herein in relation to the various disorders and diseases described herein. The diagnostic agent or biosensor is suitable for, but not limited to, detecting and / or tracking any disorder and disease described herein, respectively. Such detection is made possible by binding of a nucleic acid according to the present invention to CXCL8. This binding can be detected directly or indirectly, wherein the nucleic acid molecule may or may not contain a modifying group. In a preferred embodiment, the modifying group allows the fixation of the nucleic acid. In another preferred embodiment, the modifying group is a label. Corresponding methods and means are known to those skilled in the art.
[0394] In one embodiment, the nucleic acid of the present invention is fixed to the surface of the reaction vessel in the diagnostic agent, the surface of the device contained in the reaction vessel of the diagnostic agent, or the surface of the biosensor by any means known to those skilled in the art (including non-covalent or covalent attachment).
[0395] In a preferred embodiment, the nucleic acid according to the present invention is fixed to the surface by covalent bonding. Therefore, it is within the scope of the present invention that the nucleic acid molecule according to the present invention comprises a modifying group that allows the nucleic acid molecule to be fixed to the surface. Such modifying groups for covalent bonding include, but are not limited to (activated) carboxyl, hydroxyl, phosphatidyl, sulfonate, amine, thiol, epoxide, alkyne, strained cyclic alkyne (e.g. dibenzocyclooctyl, DBCO; bicyclo [6.1.0] nonyl-4-yne, BCN; or azadibenzocyclooctyne, ADIBO), maleimide, azide, hydrazide.
[0396] For example, such covalent linkages can be formed by the reaction of activated carboxyl groups (e.g., EDC / NHS activation) with primary amines, maleimides with thiol groups, copper-catalyzed cycloadditions of azide alkynes (click chemistry), copper-free catalyzed click chemistry (including, but not limited to, copper-free catalyzed cycloadditions of azide strained alkynes, olefin azide [3+2] cycloadditions, Diels-Alder reactions of olefin tetrazines with inversion requirements, and photo-click reactions of olefin tetrazoles), or direct coupling of thiolated probes on a gold surface. It is within the scope of the embodiments that such methods are not limited to specific stereostructures, and the reactive groups can be located on the surface or on the nucleic acid.
[0397] In a preferred embodiment, the nucleic acid of the invention is coupled to the azide-functionalized surface of the biosensor by strain-promoted azide-alkyne cycloaddition reaction (click chemistry). To this end, the surface is functionalized with an azide, while for the functionalization of the oligonucleotides, strained alkynes such as dibenzocyclooctyl, DBCO; bicyclo[6.1.0]non-4-yne (BCN) and azadibenzocyclooctyne (ADIBO) are used, preferably functionalized at the 5' or 3' end. Alternatively, the reverse geometry can be used, i.e., a biosensor functionalized with strained alkynes and azide-modified nucleic acids.
[0398] In another embodiment, the nucleic acid according to the invention is immobilized by non-covalent attachment. Thus, it is within the scope of the invention that the nucleic acid molecule according to the invention comprises a modifying group which allows the nucleic acid molecule to be attached to a surface, wherein the attachment is reversible. Such non-covalently attached modifying groups include, but are not limited to, biotin (binding to avidin, streptavidin or neutravidin), bromodeoxyuridine (binding to anti-bromodeoxyuridine antibodies), digoxigenin (binding to anti-digoxigenin antibodies) and oligonucleotides (binding to complementary oligonucleotides). The unblocked 3' end of the oligonucleotide can serve as a primer for a polymerase or as an acceptor for other nucleic acids in a ligase reaction. It is within the scope of the embodiments that such methods are not limited to a specific stereostructure and the reactive groups can be located on the surface or on the nucleic acid.
[0399] It is within the scope of the present invention that the nucleic acid molecules of the present invention are not fixed but used in solution and contain modification groups, which preferably allow detection of the nucleic acid molecules, referred to herein as labels. These labels include, but are not limited to, biotin (binding to avidin, streptavidin or neutravidin), bromodeoxyuridine (binding to anti-bromodeoxyuridine antibodies), digoxigenin (binding to anti-digoxigenin antibodies), oligonucleotides (binding to complementary oligonucleotides), fluorescent labels (e.g. fluorescein, Cy-3, Cy-5), electrochemiluminescent labels, radioactive labels, enzyme labels, UV labels, colloidal gold, nanoparticles and chelating molecular labels.
[0400] In another embodiment, the nucleic acid molecules of the invention comprise a non-nucleoside, preferably a hydrophilic linker, such as a single unit or repeating ethylene glycol, such as triethylene glycol (TEG), hexaethylene glycol (HEG) or even polyethylene glycol (PEG), which can link the nucleic acid and the modifying group together.
[0401] For the detection of CXCL8, preferred methods are direct binding to CXCL8, sandwich binding assays, competitive binding assays or lateral flow setups.
[0402] In one embodiment, CXCL8 is detected by direct binding of the immobilized nucleic acid to CXCL8. Direct binding according to the present invention is a method using only the nucleic acid according to the present invention, without a second molecule that interacts with CXCL8.
[0403] One form of the sandwich binding assay is to form an immobilized complex of CXCL8 with a nucleic acid molecule according to the invention, the nucleic acid molecule containing a modifying group for immobilization, wherein the complex is immobilized to the surface of a reaction vessel of the diagnostic agent, to the surface of a device contained in a reaction vessel of the diagnostic agent, or to the surface of a biosensor, wherein the complex is preferably detected. It is within the scope of the embodiment that CXCL8 is detected from the complex. Corresponding detection means that meet this requirement are, for example, any detection means that are specific for a certain / certain parts (epitopes) of CXCL8, which are not detected by the nucleic acid molecule of the invention, and are selected from the group comprising nucleic acids, polypeptides, proteins and antibodies, the production processes of which are known to those skilled in the art. The methodology of such sandwich binding assays is known to those skilled in the art.
[0404] It is within the scope of embodiments of the sandwich binding assay that a reverse configuration may be used, wherein the above-mentioned detection means is fixed to the surface of the reaction vessel of the diagnostic agent, to the surface of the device contained in the reaction vessel of the diagnostic agent, or to the surface of the biosensor to form a complex with CXCL8 provided in the sample, and the complex is detected by the nucleic acid molecule of the present invention. It is within the scope of this embodiment that the nucleic acid molecules according to the present invention contain a label or are not labeled. Detection of unlabeled nucleic acid molecules may involve the use of a second detection means, which is preferably also selected from the group comprising: nucleic acids, polypeptides, proteins and embodiments of the various embodiments described herein. Preferably, this detection means is specific for the nucleic acid according to the present invention.
[0405] Finally, it is also within the scope of the present invention to detect the second detection means using a third detection means, preferably the third detection means is linked to an enzyme, more preferably exhibits an enzymatic reaction when detecting the second detection means, or the third detection means is a means for detecting radiation, more preferably radiation emitted by a radionuclide. Preferably, the third detection means specifically detects the second detection means and / or specifically interacts with the second detection means.
[0406] In another embodiment, the binding of the nucleic acid molecule according to the present invention to CXCL8 is detected in a competition assay. Here, an immobilized oligonucleotide probe complementary to a portion of the nucleic acid molecule according to the present invention competes with the complex formation between the nucleic acid of the present invention and CXCL8, wherein in this embodiment, the nucleic acid molecule is not fixed to a surface. Alternatively, immobilized CXCL8 competes with the complex formation between the nucleic acid of the present invention and CXCL8, wherein in this embodiment, the nucleic acid molecule is not fixed to a surface. In another embodiment, the nucleic acid molecule according to the present invention is fixed to a surface, and the binding of CXCL8 to the immobilized nucleic acid molecule according to the present invention is competed with an oligonucleotide probe complementary to a portion of the nucleic acid molecule according to the present invention. The methodology of this assay is known to those skilled in the art.
[0407] Another preferred embodiment for the detection of CXCL8 is the use of the nucleic acid molecules according to the invention for the preparation of a biosensor. By definition, a biosensor is an analytical device for the detection of CXCL8 as an analyte, which combines a biological component such as a nucleic acid according to the invention with a physicochemical detector. The converter or detector element that converts one signal into another operates in a physicochemical manner: optical, piezoelectric, electrochemical, electrochemiluminescent, etc., which is caused by the interaction of CXCL8 with the biological element. The biosensor comprises at least one biological element covalently fixed on the surface of the biosensor. The at least one biological element covalently fixed on the surface of the biosensor is a nucleic acid according to the invention comprising a modifying group for fixation, a means for specific binding to a certain / certain epitopes of CXCL8 that do not bind to the nucleic acid of the invention, an oligonucleotide probe complementary to the nucleic acid of the invention, or CXCL8. If the nucleic acid according to the invention is not fixed to the surface of the biosensor, the nucleic acid according to the invention comprises a modifying group as a marker or does not comprise a modifying group.
[0408] The surface of the biosensor or the surface of the diagnostic agent can be selected from the following group: gold, silver, titanium, zirconium, vanadium, chromium, manganese, cobalt, tungsten, molybdenum, platinum, aluminum, iron, steel, copper, nickel, silicon, germanium, indium phosphide, gallium arsenide, and their oxides, nitrides or alloys or mixtures of the above materials, indium tin oxide, glassy carbon, sapphire and silicate glass or borate glass.
[0409] These surfaces can be further modified by polylysine, aminosilane, epoxysilane, nitrocellulose, carboxyl dextran, nanocarbon film, graphene oxide, aminographene, carbon black and other carbon surfaces, carbon fiber, carbon plate, carbon cloth, activated carbon, glassy carbon, charcoal, activated charcoal, graphite powder, graphite fiber, carbon nanotubes, fullerene, carboxyl, azide, thiol, hydroxyl, epoxide, maleimide, alkyne, strained alkyne or a combination thereof.
[0410] In a preferred embodiment, the nucleic acid molecule according to the present invention containing a modification group for immobilization is immobilized on the surface of the biosensor for direct detection of CXCL8 or detection of CXCL8 in the form of a sandwich assay or a competitive assay. In another preferred embodiment, a detection means specific for a certain epitope / s of CXCL8 not detected by the nucleic acid of the present invention (as described above), an oligonucleotide probe complementary to the nucleic acid of the present invention, or CXCL8 is immobilized on the surface of the biosensor and detected using a labeled or unlabeled nucleic acid according to the present invention (as described above) in the form of a sandwich assay or a competitive assay.
[0411] For example, detection systems in diagnostics and biosensors can be based on optical readout (fluorescence, absorption, and luminescence), mass change (e.g., quartz crystal microbalance, microelectromechanical system), refractive index (surface plasmon resonance, ring resonator, ellipsometry), charge (electrochemical impedance, voltammetry, amperometry, potentiometry, or conductivity, field effect transistors), surface stress (cantilever biosensors), and atomic force microscopy.
[0412] In another embodiment, the nucleic acid molecules according to the invention are used in a sandwich assay or a lateral flow competition assay. The methodology of such lateral flow assays is known to the person skilled in the art.
[0413] In another embodiment, the binding of the nucleic acid molecule according to the invention to CXCL8 is detected in a homologous assay by a nucleic acid probe that is complementary to a portion of the nucleic acid molecule according to the invention, wherein in such an embodiment, the nucleic acid molecule is not fixed to a surface. The hybridization here causes a change in the fluorescent signal of the two fluorescent groups connected to the nucleic acid, preferably a change in intensity, and the hybridization competes with the complex formation between the nucleic acid of the invention and CXCL8. Both fluorescent groups are connected to the nucleic acid probe (molecular beacon) or one is connected to the probe and the other is connected to the nucleic acid of the invention. In another embodiment, one or two fluorescent groups are connected to the nucleic acid of the invention, and the formation of a complex containing CXCL8 causes a change in the fluorescent signal, preferably a change in intensity. The methodology of this assay is known to those skilled in the art.
[0414] Nucleic acid molecules according to the present invention can further be used as starting materials for drug design. Basically, there are two possible ways. One way is to screen a compound library, wherein such a compound library is preferably a low molecular weight compound library. In one embodiment, this screening is a high throughput screening. Preferably, in a target-based assay, high throughput screening is a fast and efficient trial and error assessment of a compound. The best case is to utilize colorimetry to analyze. The library used in connection therewith is known to those skilled in the art.
[0415] Alternatively, nucleic acid molecules according to the present invention can be used for rational drug design. Preferably, rational drug design is the design of drug lead structure. Starting from the three-dimensional structure of the target (generally identified by methods such as X-ray crystallography or nuclear magnetic resonance spectroscopy), a computer program is used to search in the database containing many different compound structures. This selection is realized by computer, and the identified compound can be tested in the laboratory afterwards.
[0416] Rational drug design can start from any nucleic acid molecule according to the present invention, and relate to a structure similar to nucleic acid structure of the present invention or a structure identical with the mediation binding part of nucleic acid structure of the present invention, preferably, the structure is preferably a three-dimensional structure. In any case, this structure still demonstrates the same or similar binding characteristics as nucleic acid of the present invention. As a further step or optional step in rational drug design, use a chemical group that is different from nucleotides and nucleic acid to simulate the preferred three-dimensional structure of those parts that are combined with neurotransmitters in the nucleic acid molecule. Utilize this simulation, can design a compound that is different from nucleic acid according to the present invention. The preferred small molecule or peptide of this type of compound.
[0417] In the case of screening a compound library, suitable CXCL8 analogs, CXCL8 agonists or CXCL8 antagonists can be found, for example, by utilizing competitive assays known to those skilled in the art. Such competitive assays can be established in the following manner. A nucleic acid of the invention (preferably a Spiegelmer, which is a target binding L-nucleic acid) is coupled to a solid phase. In order to identify analogs of CXCL8, labeled CXCL8 can be added to the assay. Potential analogs will compete with the CXCL8 molecule for the Spiegelmer, which will be accompanied by a decrease in the signal generated by the corresponding marker. Screening for agonists or antagonists may involve the use of cell culture assays known to those skilled in the art.
[0418] The kit according to the present invention may comprise at least one or several nucleic acid molecules of the present invention. In addition, the kit may comprise at least one or several positive or negative controls. For example, the positive control may be CXCL8, in particular, CXCL8 to which the nucleic acid of the present invention is selected or CXCL8 to which the nucleic acid of the present invention is bound, preferably in liquid form. For example, the negative control may be a peptide, which is defined as being similar to CXCL8 in terms of biophysical characteristics, but which is not recognized by the nucleic acid of the present invention. Moreover, the kit may comprise one or more buffers. The kit may comprise a plurality of components, which may be in dry form, lyophilized form or dissolved in a liquid. The kit may comprise one or more containers, which may be filled with one or more components of the kit in turn. In another embodiment, the kit comprises instructions or instruction leaflets, which provide the user with information on how to use the kit and its various components.
[0419] Pharmaceutical and bioanalytical assays of nucleic acid molecules according to the present invention are necessary for evaluating their pharmacokinetic and biokinetic profiles in various body fluids, tissues and organs of humans and non-humans. For this purpose, any detection method disclosed herein or any detection method known to those skilled in the art can be used. In another aspect of the present invention, a sandwich hybridization assay for detecting nucleic acids according to the present invention is provided. In this detection assay, a capture probe and a detection probe are used. The capture probe is complementary to the first portion of the nucleic acid according to the present invention, and the detection probe is complementary to the second portion of the nucleic acid according to the present invention. Both the capture probe and the detection probe can be formed by DNA nucleotides, modified DNA nucleotides, modified RNA nucleotides, RNA nucleotides, LNA nucleotides and / or PNA nucleotides.
[0420] Therefore, the capture probe contains a sequence segment complementary to the 5' end of the nucleic acid molecule according to the present invention, and the detection probe contains a sequence segment complementary to the 3' end of the nucleic acid molecule according to the present invention. In this case, the capture probe is fixed to a surface or matrix via its 5' end, wherein the capture probe can be directly fixed at its 5' end, or fixed via a joint between its 5' end and the surface or matrix. However, in principle, the joint can be connected to each nucleotide of the capture probe. The joint can be formed by a hydrophilic joint in the art, or by D-DNA nucleotides, modified D-DNA nucleotides, D-RNA nucleotides, modified D-RNA nucleotides, D-LNA nucleotides, PNA nucleotides, L-RNA nucleotides, L-DNA nucleotides, modified L-RNA nucleotides, modified L-DNA nucleotides and / or L-LNA nucleotides.
[0421] Alternatively, the capture probe contains a sequence segment complementary to the 3' end of the nucleic acid molecule according to the present invention, and the detection probe contains a sequence segment complementary to the 5' end of the nucleic acid molecule according to the present invention. In this case, the capture probe is fixed to a surface or matrix via its 3' end, wherein the capture probe can be directly fixed at its 3' end, or fixed via a joint between its 3' end and the surface or matrix. However, in principle, the joint can be connected to each nucleotide of the sequence segment complementary to the nucleic acid according to the present invention. The joint can be formed by a hydrophilic joint in the art, or by D-DNA nucleotides, modified D-DNA nucleotides, D-RNA nucleotides, modified D-RNA nucleotides, D-LNA nucleotides, PNA nucleotides, L-RNA nucleotides, L-DNA nucleotides, modified L-RNA nucleotides, modified L-DNA nucleotides and / or L-LNA nucleotides.
[0422] The number of nucleotides of the capture probe and the detection probe that can hybridize with the nucleic acid molecule according to the present invention is variable and can depend on the number of nucleotides of the capture probe and / or the detection probe and / or the nucleic acid itself according to the present invention. The total number of nucleotides of the capture probe and the detection probe that can hybridize with the nucleic acid according to the present invention should be at most the number of nucleotides contained in the nucleic acid according to the present invention. The minimum number of nucleotides in the detection probe and the capture probe (2 to 10 nucleotides) should allow it to hybridize with the 5' end or 3' end of the nucleic acid according to the present invention, respectively. In order to achieve high specificity and selectivity between the nucleic acid according to the present invention and other nucleic acids present in the analyzed sample, the total number of nucleotides in the capture probe and the detection probe should be or be at most the number of nucleotides contained in the nucleic acid molecule according to the present invention.
[0423] Moreover, preferably, the detection probe carries a marker molecule or a label detectable as described herein before. The marker or marker molecule can be connected to each nucleotide of the detection probe in principle. Preferably, the marker or marker is located at the 5' end or 3' end of the detection probe, wherein a linker can be inserted between the nucleotides in the detection probe complementary to the nucleic acid molecule according to the present invention and the marker. The linker can be formed by a hydrophilic linker in the art, or by D-DNA nucleotides, modified D-DNA nucleotides, D-RNA nucleotides, modified D-RNA nucleotides, D-LNA nucleotides, PNA nucleotides, L-RNA nucleotides, L-DNA nucleotides, modified L-RNA nucleotides, modified L-DNA nucleotides and / or L-LNA nucleotides.
[0424] Detection of nucleic acids according to the present invention can be performed as follows:
[0425] The nucleic acid molecule according to the present invention is hybridized with the capture probe at one end thereof and with the detection probe at the other end thereof. The unbound detection probe is then removed, for example, by one or more washing steps. Subsequently, the amount of the bound detection probe (preferably with a label or marker molecule) can be measured, for example, as discussed in detail in WO / 2008 / 052774, the contents of which are incorporated herein by reference.
[0426] As preferably used herein, the term treatment in a preferred embodiment additionally or alternatively comprises prevention and / or follow-up.
[0427] As preferably used herein, the terms disease and disorder should be used interchangeably if not indicated to the contrary.
[0428] As used herein, the term includes / comprising is preferably not intended to limit the subject matter preceding such term or the subject matter described by such term. However, in optional embodiments, the term includes / comprising should be understood to mean containing, and is thus understood to limit the subject matter preceding such term or the subject matter described by such term.
[0429] The individual SEQ.ID.No:, chemical properties, actual sequences and internal reference numbers of the nucleic acid molecules and target molecule CXCL8 according to the present invention as used herein are summarized in the table below.
[0430]
[0431]
[0432]
[0433]
[0434]
[0435]
[0436]
[0437] The features of the invention disclosed in the specification, claims, sequence listing and / or drawings, whether in separate forms or in any combination thereof, may be used as material to realize the invention in its various forms.
[0438] The present invention is further illustrated by the accompanying drawings, examples and sequence listings, from which further features, embodiments and advantages can be seen, wherein
[0439] Figure 1Shown is a sequence alignment of nucleic acid molecules capable of binding to human CXCL8, including K determined by competitive pull-down binding assay. D value;
[0440] Figure 2 Truncated derivatives of nucleic acid molecule 315-F8-001 are shown, including K determined by competitive pull-down binding assays and / or surface plasmon resonance measurements. D Values and relative binding activity to human CXCL8;
[0441] Figure 3 Shown is the kinetic evaluation between D-nucleic acid molecules 315-F8-001 and 315-F8-002 and D-CXCL8 by competitive pull-down binding assay;
[0442] Figure 4 The binding of nucleic acid molecule 315-F8-002 to CXCL8 determined by surface plasmon resonance measurement at (A) 25° C. and (B) 37° C. is shown. The binding constant ka and the dissociation constant kd are given;
[0443] Figure 5 The binding of the nucleic acid molecule 315-F8-002-PEG to CXCL8 as determined by surface plasmon resonance measurements at (A) 25° C. and (B) 37° C. is shown. The binding constant ka and the dissociation constant kd are given;
[0444] Figure 6 Shown is the selectivity of 315-F8-002 binding to CXCL8 as measured by surface plasmon resonance and determined by competitive binding assay;
[0445] Figure 7 The inhibition of CXCL8-induced chemotaxis of CXCR2-expressing cells by the nucleic acid molecule 315-F8-002-PEG is shown;
[0446] Figure 8 is a bar graph showing the use of nucleic acid molecule 315-F8-002 ( Figure 8 A) Quantification and expression of CXCL8 using nucleic acid molecule 315-F8-002 ( Figure 8 B) quantification of CCL5; and
[0447] Fig. 9 is a bar graph showing the activity of L-aptamer 315-F8-002 ( Fig. 9 A) and aptamer 8A-35 ( Fig. 9 B) Binding to soluble CXCL8 and CXCL1.
[0448] Example 1:Nucleic acid capable of binding to human CXCL8
[0449] Several CXCL8-binding nucleic acids and their derivatives have been identified, and their nucleotide sequences are Figure 1-2 D-aptamer (D-nucleic acid) and L-aptamer (L-nucleic acid) were tested as CXCL8 binding nucleic acids, wherein the synthesis of D-nucleic acid and L-nucleic acid was as described in Example 2.
[0450] CXCL8 binding nucleic acids are characterized by:
[0451] a) testing the binding of the D-aptamer to biotinylated D-CXCL8 (SEQ ID NO: 1) by a pull-down binding assay, as described in Example 3; and
[0452] b) The L-aptamers were tested by surface plasmon resonance (SPR) measurements (Example 4) and by in vitro assays using cells expressing the human CXCR2 receptor, wherein L-CXCL8 (SEQ ID NO: 2) was used for both approaches (Example 5).
[0453] The nucleic acids thus generated display slightly different sequences, which can be summarized or grouped into sequence families.
[0454] To define nucleotide sequence motifs, the following IUPAC abbreviations for ambiguous nucleotides are used:
[0455] S strong G or C;
[0456] W weak A or U(T);
[0457] R purine G or A;
[0458] Y pyrimidine C or U (T);
[0459] K contains keto group G or U (T);
[0460] M contains imino group A or C;
[0461] B is not AC or U(T) or G;
[0462] D is not CA or G or U(T);
[0463] H is not GA or C or U(T);
[0464] V is not UA or C or G;
[0465] N all A or G or C or U (T)
[0466] If not indicated to the contrary, any nucleic acid sequence or segment sequence, respectively, is expressed in the 5'→3' direction.
[0467] like Figure 1-2 As shown, the CXCL8 binding nucleic acid comprises a central nucleotide segment defining a potential CXCL8 binding motif, wherein Figure 1 The different sequences of the sequence family are shown, Figure 2 Truncated derivatives of the CXCL8 binding nucleic acid 315-F8-001 are shown, including the CXCL8 binding nucleic acid 315-F8-002-PEG.
[0468] Generally speaking, the CXCL8 binding nucleic acid molecule comprises terminal nucleotide segments located at its 5'-end and 3'-end: a first terminal nucleotide segment and a second terminal nucleotide segment. The first terminal nucleotide segment and the second terminal nucleotide segment can hybridize with each other, wherein a double-stranded structure is formed when hybridized. However, under in vivo conditions and in vitro conditions, such hybridization does not necessarily occur in the molecule.
[0469] The three nucleotide segments of the CXCL8-binding nucleic acid molecule, i.e., the first terminal nucleotide segment, the central nucleotide segment, and the second terminal nucleotide segment, are arranged in a 5'→3' direction as follows: first terminal nucleotide segment-central nucleotide segment-second terminal nucleotide segment. However, alternatively, the first terminal nucleotide segment, the central nucleotide segment, and the second terminal nucleotide segment are arranged in a 5'→3' direction as follows: second terminal nucleotide segment-central nucleotide segment-first terminal nucleotide segment.
[0470] The sequences of the defined segments may vary between CXCL8 binding nucleic acid molecules, which may affect their binding affinity to CXCL8. Based on binding analysis of different CXCL8 binding nucleic acid molecules, the central nucleotide segment and its nucleotide sequence as described below are individually and more preferably collectively essential for binding to CXCL8.
[0471] CXCL8 binding nucleic acid is composed of ribonucleotides (such as Figure 1-2 shown).
[0472] like Figure 1 As shown, the sequences of the central nucleotide segments in the CXCL8 binding nucleic acids 315-H9-001, 315-F11-001 and 315-F8-001 are slightly different:
[0473] 5'GGAAGUACGUGGAAAGCCAAUGAGUGUGUCCCG 3'(315-H9-001),
[0474] 5'GGAAGUACGUGGAAAGCCGAUGAGUGUGUCCCG 3'(315-F11-001),
[0475] 5'GGAAGUACGUGGAAAGCCGAAAGUGUGUCCCG 3'(315-F8-001).
[0476] The central nucleotide segment of the CXCL8 binding nucleic acid according to the present invention comprises 32-33 nucleotides and can be summarized as the following consensus sequence:
[0477] 5'GGAAGUACGUGGAAAGCCRA(X U )RAGUGUGUCCCG 3', where X U Is U or does not exist.
[0478] The CXCL8-binding nucleic acid has the best binding affinity to CXCL8, which means that the CXCL8-binding nucleic acid has the highest binding affinity to CXCL8 or has the smallest dissociation constant Kd with CXCL8. Such nucleic acid comprises a central nucleotide segment having the following sequence: 5'GGAAGUACGUGGAAAGCCGAAAGUGUGUCCCG 3'(315-F8-001) and 5'GGAAGUACGUGGAAAGCCAAUGAGUGUGUCCCG 3'(315-H9-001), wherein the central nucleotide segment having the sequence 5'GGAAGUACGUGGAAAGCCGAAAGUGUGUCCCG3'(315-F8-001) contributes to the best binding affinity of the CXCL8-binding nucleic acid to CXCL8.
[0479] like Figure 1 and 2 As shown, the first terminal nucleotide segment and the second terminal nucleotide segment of the CXCL8 binding nucleic acid contain 6 nucleotides, 5 nucleotides, 4 nucleotides or 3 nucleotides, wherein these segments are optionally hybridized to each other, wherein a double-stranded structure is formed upon hybridization. Such a double-stranded structure may consist of 6, 5, 4 or 3 base pairs. However, such hybridization does not necessarily occur in the molecule.
[0480] like Figure 1 As shown, the first nucleotide segment and the second nucleotide segment in the CXCL8 binding nucleic acids 315-H9-001, 315-F11-001 and 315-F8-001 respectively contain 6 nucleotides:
[0481] a) CXCL8 binding nucleic acids 315-H9-001 and 315-F8-001 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'GCUGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAGC3';
[0482] b) CXCL8-binding nucleic acid 315-F11-001 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'GCUGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUGAGC3'.
[0483] like Figure 2 As shown, the first nucleotide segment and the second nucleotide segment in the CXCL8-binding nucleic acid contain 5 nucleotides, 4 nucleotides or 3 nucleotides, respectively:
[0484] a) CXCL8 binding nucleic acid 315-F8-002 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'CUGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAG3';
[0485] b) CXCL8-binding nucleic acid 315-F8-005 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'GUGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAC3';
[0486] c) CXCL8-binding nucleic acid 315-F8-003 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'UGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCA3';
[0487] d) CXCL8-binding nucleic acid 315-F8-006—the first terminal nucleotide segment comprises a nucleotide sequence of 5'GGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCC3';
[0488] e) CXCL8 binding nucleic acid 315-F8-007 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'GCAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUGC3';
[0489] f) CXCL8 binding nucleic acid 315-F8-008 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'GGUC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GACC3';
[0490] g) CXCL8 binding nucleic acid 315-F8-009 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'UGGC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GCCA3';
[0491] h) CXCL8 binding nucleic acid 315-F8-004 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'GAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUC3'.
[0492] The first terminal nucleotide segment and the second terminal nucleotide segment of all tested CXCL8 binding nucleic acid molecules can be summarized as the following general formula of the first terminal nucleotide segment and the second terminal nucleotide segment:
[0493] The general formula of the first terminal nucleotide segment is 5'Z1Z2Z3Z4Z5C3', and the general formula of the second terminal nucleotide segment is 5'GZ6Z7Z8Z9Z 10 3', wherein Z1 is G or absent, Z2 is S or absent, Z3 is K or absent, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M or absent, Z9 is S or absent, and Z 10 is C or does not exist,
[0494] Among them, in the first preferred embodiment
[0495] q) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0496] r) Z1 is absent, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0497] s) Z1 is not present, Z2 is not present, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is not present, and Z 10 does not exist; or
[0498] t) Z1 is not present, Z2 is not present, Z3 is not present, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is not present, Z9 is not present, and Z 10 does not exist; or
[0499] u) Z1 is absent, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0500] v) Z1 is absent, Z2 is absent, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0501] w) Z1 is absent, Z2 is absent, Z3 is absent, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 is C; or
[0502] x) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0503] y) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is absent, and Z 10 does not exist; or
[0504] z) Z1 is G, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is not present, Z9 is not present, and Z 10 does not exist; or
[0505] aa) Z1 is not present, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is not present, and Z 10 does not exist; or
[0506] bb) Z1 is not present, Z2 is S, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is not present, Z9 is not present, and Z 10 does not exist; or
[0507] cc) Z1 is absent, Z2 is absent, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0508] dd) Z1 is not present, Z2 is not present, Z3 is not present, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is S, and Z 10 does not exist; or
[0509] ee) Z1 is not present, Z2 is not present, Z3 is K, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is not present, Z9 is not present, and Z 10 does not exist; or
[0510] ff) Z1 is not present, Z2 is not present, Z3 is not present, Z4 is S, Z5 is D, Z6 is H, Z7 is S, Z8 is M, Z9 is not present, and Z 10 Does not exist.
[0511] The CXCL8-binding nucleic acid has the best binding affinity to CXCL8, which means that the CXCL8-binding nucleic acid has the highest binding affinity to CXCL8 or has the smallest dissociation constant Kd to CXCL8, and such nucleic acid comprises the following first and second terminal nucleotide segments:
[0512] a) CXCL8 binding nucleic acids 315-H9-001 and 315-F8-001 - the first terminal nucleotide segment comprises a nucleotide sequence of 5'GCUGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAGC3';
[0513] b) CXCL8-binding nucleic acid 315-F8-002—the first terminal nucleotide segment comprises a nucleotide sequence of 5'CUGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAG3';
[0514] c) CXCL8-binding nucleic acid 315-F8-005—the first terminal nucleotide segment comprises a nucleotide sequence of 5'GUGAC3', and the second terminal nucleotide segment comprises a nucleotide sequence of 5'GUCAC3'.
[0515] By competitive pull-down binding assay, the Kd values of CXCL8 binding nucleic acids 315-F8-001, 315-H9-001 and 315-F11-001 (comprising a terminal segment with 6 nucleotides) were determined to be in the range of 1.5-12.5 nM ( Figure 1-3 ). In the direct pull-down assay format, the CXCL8 binding nucleic acid 315-F8-001 showed a Kd value of 0.8 nM. For determining the Kd value, the surface plasmon resonance measurement method is more sensitive, and the Kd value of CXCL8 binding nucleic acid 315-F8-001 at 25°C was 0.22 nM, and the Kd value at 37°C was 0.68 nM ( Figure 2 ).
[0516] Surprisingly, it was found that truncating the first terminal segment from 6 to 5 nucleotides and truncating the second terminal segment from 6 to 5 nucleotides did not have any negative effect on the binding affinity to CXCL8. The binding affinity of the CXCL8 binding nucleic acid 315-F8-002 was measured by competitive pull-down assay (Kd value of 1.1 nM, Figure 2 and 3 ), and its binding affinity was measured by surface plasmon resonance measurement (Kd value at 25°C was 0.22 nM, while Kd value at 37°C was 0.75 nM, Figure 2 and 4), these Kd values are within the binding affinity range determined for the CXCL8 binding nucleic acid 315-F8-001 (see Kd values for 315-F8-001 described above).
[0517] Attempts were made to further truncate and / or mutate the terminal segment of the CXCL8-binding nucleic acid 315-F8-002, resulting in the following CXCL8-binding nucleic acids 315-F8-003, 315-F8-004, 315-F8-005, 315-F8-006, 315-F8-007, 315-F8-008, and 315-F8-009, which have reduced binding affinity to CXCL8 (315-F8-003, 315-F8-004, 315-F8-006, 315-F8-007, 315-F8-008, and 315-F8-009) or similar. Figure 2 ).
[0518] As a variant of the 5'-40 kDa-PEGylated CXCL8-binding nucleic acid 315-F8-002, the CXCL8-binding nucleic acid 315-F8-002-PEG (also known as AON-S08) had a Kd value of 0.2 nM at 25°C and a Kd value of 0.8 nM at 37°C as measured by surface plasmon resonance measurement ( Figure 2 and 5 ).
[0519] CXCL8 is one of a variety of ELR-positive human CXC chemokines. In addition to CXCL8, ELR-positive human CXC chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7 bind to the CXCL8 receptor CXCR2, of which ELR-positive human CXC chemokines CXCL6 and CXCL7 also bind to the CXCL8 receptor CXCR1. In order to show the specificity and selectivity of the binding characteristics of CXCL8-binding nucleic acid 315-F8-002, the binding affinity of CXCL8-binding nucleic acid 315-F8-002 to ELR-positive human CXC chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7 was tested by SPR in a competitive binding assay (Example 4). CXCL8-binding nucleic acid 315-F8-002 showed that it did not bind to any other ELR-positive human CXC chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7 ( Figure 6 ).
[0520] The CXCL8-binding nucleic acid 315-F8-002-PEG inhibited the CXCL8-induced chemotaxis of BA / F3 cells expressing CXCR2 with a mean inhibition constant IC50 of 0.26 nM ( Figure 7 , Example 5).
[0521] A biosensor with immobilized CXCL8 binding nucleic acid 315-F8-002 was used to detect and quantify CXCL8. The limit of detection (mean baseline value + 3 times the standard deviation of the baseline value) was <98 pM CXCL8, and the lower limit of quantification (mean baseline value + 10 times the standard deviation of the baseline value) was also <98 pM CXCL8 ( Figure 8 A, Example 6). To demonstrate the specificity of the immobilized CXCL8 binding nucleic acid 315-F8-002, a different chemokine (CCL5) was used as analyte. No binding to CCL5 was detected at concentrations up to 12.5 nM ( Figure 8 B, Example 6).
[0522] Example 2 :Synthesis of D-aptamers and L-aptamers
[0523] Small-scale solid phase synthesis
[0524] D-aptamers (D-nucleic acids) and L-aptamers (L-nucleic acids) were generated by solid phase synthesis using 2'-TBDMS RNA phosphoramidite chemistry (Damha and Ogilvie, 1993) using an ABI 394 synthesizer (Applied Biosystems, Foster City, CA, USA). L-rA(N-Bz)-, L-rC(Ac)-, L-rG(N-ibu)-, L-rU-, D-rA(N-Bz)-, D-rC(Ac)-, D-rG(N-ibu)- and D-rU-phosphoramidites were purchased from ChemGenes, Wilmington, MA. D-aptamers and L-aptamers were purified by gel electrophoresis.
[0525] Large-scale solid phase synthesis
[0526] Using 2'-TBDMS RNA and DNA phosphoramidite chemistry (Damha and Ogilvie, 1993), L-aptamers were generated by solid phase synthesis using a 5′-amino-modified CPG synthesizer (Amersham Biosciences; General Electric Healthcare, Freiburg). L-rA(N-Bz)-, L-rC(Ac)-, L-rG(N-ibu)-, and L-rU- were purchased from ChemGenes, Wilmington, MA. 5′-amino-modifiers were purchased from American International Chemicals Inc. (Framingham, MA, USA). The synthesis of unmodified or 5′-amino-modified L-aptamers was initiated with L-riboA, L-riboC, L-riboG, or L-riboU, and the modified CPG had a pore size of 1000 Å (Link Technology, Glasgow, UK. For the coupling of RNA phosphoramidites (15 min per cycle), 0.3 M benzylthiotetrazole in acetonitrile (CMS-Chemicals, Abingdon, UK) and 2 equivalents of the corresponding 0.2 M phosphoramidite solution in acetonitrile were used. Oxidation-capping cycles were used. Other standard solvents and reagents required for oligonucleotide synthesis were purchased from Biosolve (Valkenswaard, NL). L-aptamers were synthesized as DMT-ON; after deprotection, they were purified by preparative RP-HPLC (Wincott et al. 1995) using SOURCE5RPC medium (Amersham). The 5'DMT-group was removed with 80% acetic acid (30 min at room temperature). In the case of L-aptamers undergoing 5'-amino modification, the 5'MMT-group was eluted with 80% acetic acid (90 min at room temperature). Subsequently, 2M The L-aptamer was desalted by tangential flow filtration using a 5K regenerated cellulose membrane (Millipore, Bedford, MA).
[0527] PEGylation of L-aptamers
[0528] In order to prolong the plasma residence time of the L-aptamer in vivo, the L-aptamer was covalently coupled to a 40 kDa polyethylene glycol (PEG) moiety at the 5'-end. For PEGylation (technical details of the PEGylation method are provided in European patent application EP 1 306382), the purified 5'-amino-modified L-aptamer was dissolved in a mixture of H2O (2.5 ml), DMF (5 ml) and buffer A (5 ml; prepared by mixing citric acid·H2O [7 g], boric acid [3.54 g], phosphoric acid [2.26 ml] and 1 M NaOH [343 ml], and adding water to a final volume of 1 L; pH = 8.4 was adjusted with 1 M HCl).
[0529] The pH of the L-aptamer solution was adjusted to 8.4 with 1 M NaOH. Then, 40 kDa PEG-NHS ester (Jenkem Technology, Allen, TX, USA) was added every 30 min at 37° C. in 6 portions (0.25 equivalents each) until the maximum yield reached 75-85%. During the addition of PEG-NHS ester, the pH of the reaction mixture was stabilized at 8–8.5 with 1 M NaOH.
[0530] The reaction mixture was mixed with 4 ml of urea solution (8 M) and 4 ml of buffer B (0.1 M triethylammonium acetate in water) and heated to 95°C for 15 min. The PEGylated L-aptamer was purified by RP-HPLC using Source 15RPC medium (Amersham) under an acetonitrile gradient (buffer B; buffer C: 0.1 M triethylammonium acetate in acetonitrile). 5% of buffer C eluted the excess PEG and 10–15% of buffer C eluted the PEGylated L-aptamer. Product fractions with a purity of >95% (assessed by HPLC) were combined and mixed with 40 ml of 3 M NaOAc. The PEGylated L-aptamer was desalted by tangential flow filtration (5K regenerated cellulose membrane, Millipore, Bedford MA).
[0531] Example 3 : Pull-down binding assay
[0532] Direct pull-down assay for determination of D-aptamer binding constants
[0533] A direct pull-down assay was used to determine the affinity of the D-aptamers for D-CXCL8 (C-bio) (SEQ ID NO: 1). 32P]-ATP (Hartmann Analytic, Braunschweig, Germany), and the D-aptamer was radiolabeled by T4 polynucleotide kinase (Invitrogen, Karlsruhe, Germany). The specific radioactivity of the labeled D-aptamer was 110,000–300,000 cpm / pmol. The labeled D-aptamer was incubated at a concentration of 0.2 nM with different amounts of D-CXCL8 (C-bio) (concentration range 0.0192 to 300 nM) at 37°C in selection buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 0.1% Tween20, 100 μg / ml essential fatty acid-free bovine serum albumin, 200 μg / ml yeast RNA) for 1.5–2 hours. The complex of D-CXCL8 (C-bio) / D-aptamer was fixed on NAag + beads (neutravidin agarose plus, Pierce Biotechnology, Rockford, USA) pre-equilibrated in the selection buffer. After separation of the supernatant and appropriate washing, the radioactivity bound to the beads was measured in a scintillation counter (LS6500; Beckman Coulter, Fullerton, USA). The amount of immobilized labeled D-aptamer (percentage of binding) was plotted against the concentration of D-CXCL8 (C-bio), and the dissociation constant Kd was obtained by using a software algorithm (GRAFIT; Erithacus Software; Surrey UK) assuming a 1: 1 stoichiometry.
[0534] For the CXCL8 binding aptamers 315-H9-001 and 315-F8-001, their Kd values were determined to be 1.7 nM and 0.8 nM, respectively, by direct pull-down assay.
[0535] Competitive pull-down assay for ranking and determining binding constants of D-aptamers
[0536] The competitive pull-down assay is used to compare the affinity of different D-CXCL8 (C-bio) binding D-aptamers. For this purpose, the D-aptamer reference is radiolabeled (as described above) and incubated in a selection buffer at 37°C with D-CXCL8 (C-bio), and the conditions of this incubation make it possible to produce non-saturated binding signals (e.g., 3nM D-CXCL8 (C-bio), 0.15nM labeled D-aptamers) after being fixed to NAag+ beads and washed. Add an excess of unlabeled D-aptamers and compete with labeled D-aptamers to bind D-CXCL8 (C-bio), which will cause beads to bind, fix and wash after the amount of radioactivity is reduced. The degree of signal reduction depends on the amount and affinity of the unlabeled D-aptamers. The competitive pull-down assay is used for sorting experiments and determining the dissociation constant (Kd) of selected D-aptamers. The dissociation constant Kd was determined by plotting the fraction (in %) of labeled D-aptamer bound to D-CXCL8 (C-bio) versus the concentration of unlabeled competing D-aptamer. Data analysis was performed using GRAFIT.
[0537] The results of the pull-down binding assay are described in Example 1 and are shown in Figure 1 , 2 and 3, wherein a labeled D-aptamer, CXCL8 binding nucleic acid 315-F8-001, was used.
[0538] Example 4 :Surface plasmon resonance (SPR) binding assay
[0539] Surface plasmon resonance measurements were performed on a Biacore 2000 instrument (GE Healthcare) set at a constant temperature of 25°C or 37°C. Proteins were immobilized on CM4 sensor chips (GE Healthcare) by amine coupling. The surface of the sensor chip was activated by injecting a 1:1 mixture of 0.4M EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; GE) and 0.1M NHS (N-hydroxysuccinimide; GE). For covalently immobilized peptides or proteins, the maximum response observed was approximately 500RU. The flow cell was blocked with 1M ethanolamine hydrochloride (GE, BR-1000-50). Non-covalently bound peptides or proteins were also removed by this procedure. Flow cells with untreated dextran surfaces and flow cells with ethanolamine-blocked surfaces were used as controls. Prior to measurements, the sensor chip was primed twice with degassed physiological running buffer (20 mM Tris pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1 mM CaCl2) and subjected to at least three cycles of injection and regeneration (5 M NaCl).
[0540] The binding affinity was measured by injecting a series of L-aptamers, i.e., 1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.9, 1.95, 0.98, 0.49, 0.24, 0.12, 0.06 nM, and recording the association and dissociation phases of the binding events. The resulting binding curves were fitted to a Langmuir stoichiometric 1:1 binding model to determine the binding kinetic rate constants (binding constant ka; dissociation constant kd) for calculation of the dissociation constant (Kd = kd / ka). Data analysis was performed using BIAevaluation 3.1.1 software (BIACORE AB, Uppsala, Sweden) with a constant refractive index (RI) value and an initial mass transfer coefficient kt of 1 x 10e7 (RU·M -1 s -1 ).
[0541] By competitive binding assay, the selectivity of L-aptamer combination is assessed.For this purpose, human chemokine CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 (purchased from RnD Systems, PeproTech or ProSpecTech) are injected with 40nM respectively with the L-aptamer (0.25nM) of CXCL8 associative nucleic acid 315-F8-002, to be competitively combined with immobilized CXCL8 L-aptamer.As a control, chemokine is injected to monitor the combination of dextran matrix and / or immobilized CXCL8 with sensor chip in the absence of L-aptamer.At predetermined reporting point, 240 seconds after injection, record 315-F8-002 and immobilized CXCL8 combination.Selected chemokine is fixed, and the binding affinity (as described above) of the L-aptamer of CXCL8 associative nucleic acid 315-F8-002 is determined.
[0542] The results of the SPR binding assay are described in Example 1 and are presented in Figure 2 , 4 , 5 and 6.
[0543] Example 5 : In vitro pharmacology - chemotaxis assay
[0544] The BA / F3 mouse primary B cell line was stably transfected with a plasmid encoding human CXCR2. For the chemotaxis assay, recombinant CXCL8 (0.5 nM) was preincubated with the indicated concentrations of the L-aptamer of the CXCL8 binding nucleic acid 315-F8-002-PEG in HBH buffer (Hanks buffered saline solution (HBSS) + 1 mg / ml BSA + 20 mM HEPES) in the lower chamber of a Corning 96-well Transwell plate with 5 um pores (Costar Corning, NY) at 37°C for 20-30 minutes. + Cells were added to the upper chamber and allowed to migrate for 3 hours at 37°C. After removing the upper chamber, 50 μM resazurin (Sigma-Aldrich) dissolved in PBS was added to the lower chamber and incubated at 37°C for 2.5 hours. Fluorescence was measured at 590 nm (excitation wavelength 544 nm). Background-corrected and standardized fluorescence values were plotted against the concentration of L-aptamers. The inhibition constant IC was determined by nonlinear regression (4-parameter fitting) using Prism 5 software (GraphPad Software, San Diego, CA). 50 value (the concentration of L-aptamer required for half-maximal inhibition).
[0545] The results of the chemotaxis assay are described in Example 1 and are presented in Figure 7 middle.
[0546] Example 6 :CXCL8 Biosensor
[0547] An SPR sensor chip coated with an azide-terminated carbon nanofilm was prepared, and the CXCL8-binding L-aptamer 315-F8-002-DBCO (a DBCO-modified variant of 315-F8-002-amino) was immobilized on a flow cell of a commercial Biacore system at a concentration of 20 μM (dissolved in 2 M NaCl) (to about 1000 RU). As a reference, a non-functional L-aptamer (DBCO-modified reverse 315-F8-002-amino) was immobilized in a similar amount on another flow cell. The surface was passivated by immobilizing DBCO-modified linear methoxy-terminated polyethylene glycol (MW: 5 kDa). A series of concentrations of the analyte CXCL8 were injected and spiked with a standard sample buffer (Universal Transport Medium from Copan) supplemented with 0.1% (w / v) Tween 20, which showed a dose-dependent signal increase. The measurement temperature was set at 25°C, the flow rate was 30 μL / min, and the running buffer was the measurement buffer (20 mM Tris pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 0.1% (w / v) Tween 20). The analyte was allowed to bind for 10 minutes, and then the dissociation time in the measurement buffer was 2.5 minutes. The signal at the end of the dissociation phase was corrected by subtracting the signal of the reference flow cell.
[0548] The results of the CXCL8 biosensor are described in Example 1 and are presented in Figure 8 middle.
[0549] Example 7 : Comparison of binding to soluble chemokines using SPR binding assay
[0550] The inhibitory activity of the aptamer depends on the ability to bind to its target in solution. Competitive SPR binding assays were used here to determine the binding of the L aptamer of the CXCL8 binding nucleic acid 315F8 002 according to the present invention and the previously published aptamer 8A-35 (see Sung, Biomaterials 2014) to soluble CXCL8 and CXCL1. For this purpose, the SPR assay was performed according to the operation described in Example 4, i.e., CXCL8 was fixed to a C1 sensor chip (GE Healthcare) by amine coupling. The binding of 315F8 002 (3nM) or 8A-35 (1.6nM) to immobilized CXCL8 produced a binding response of approximately 20 response units. In the binding assay of 8A-35, the sensor chip was regenerated using a 1M CaCl2 solution. To evaluate the binding of these two aptamers to their targets in solution, soluble CXCL8 was co-injected at equimolar concentrations (ratio 1:1) or 5-fold excess (ratio 1:5) to compete with immobilized CXCL8 for aptamer binding. Binding to soluble CXCL1 was used as a control. All assays were performed at 37°C. Binding responses to immobilized CXCL8 were recorded 240 seconds after injection.
[0551] The binding of 315-F8-002 to immobilized CXCL8 was completely blocked (>90%) by equimolar concentrations of soluble CXCL8 ( Fig. 9 In contrast, the binding of 8A35 was only partially blocked by equimolar (about 30%) and 5-fold excess (about 45%) concentrations of soluble CXCL8 ( Fig. 9 B). This indicates that 315-F8-002 has a higher binding affinity to soluble CXCL8 than 8A-35. The reduced binding affinity to soluble CXCL8 may explain the weak inhibitory activity observed for 8A-35 in the CXCL8-induced neutrophil migration assay (Sung, Biomaterials 2014).
[0552] Since 315-F8-002 showed no cross-reactivity to other ELR-positive chemokines, soluble CXCL1 was used as a control ( Figure 6 Consistent with this, the binding of 315-F8-002 was not blocked by soluble CXCL1 ( Fig. 9 A). Unexpectedly, 8A-35 binding was blocked by soluble CXCL1 with a potency similar to that by soluble CXCL8 (approximately 25% at equimolar concentrations and approximately 35% at a 5-fold excess) ( Fig. 9 B). This indicates that, in contrast to 315-F8-002, 8A-35 does not selectively bind and inhibit CXCL8 in solution as expected.
[0553] References
[0554] Unless otherwise indicated, the complete bibliographic data for documents cited herein are as follows, the disclosures of which are incorporated herein by reference.
[0555] Altschul SF,Gish W,Miller W,Myers EW,Lipman DJ(1990),Basic local alignment search tool.J Mol Biol.215(3):403-10;
[0556] Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17):3389-402;
[0557] Bao, Z. et al. (2010), Humanized monoclonal antibody against the chemokineCXCL-8(IL-8) effectively prevents acute lung injury. Int Immunopharmacol.10(2):259-63;
[0558] Brand, HK et al (2013), CD4+T-cell counts and interleukin-8and CCL-5plasma concentrations discriminate disease severity in children with RSVinfection. Pediatr Res.73(2):187-93;
[0559] Brat, D.J., A.C. Bellail, and E.G. Van Meir (2005), The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 7(2):122-33;
[0560] Campbell, L.M., P.J. Maxwell, and D.J. Waugh (2013), Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals (Basel). 6(8):929-59;
[0561] Chen, Y. et al. (2012), Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 18(10):1123-9;
[0562] David, J.M. et al. (2016), The IL-8 / IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines (Basel). 4(3):22;
[0563] Fang, Q.I. et al. (2017), Increased CXCL8 Expression Is Negatively Correlated with the Overall Survival of Patients with ER-Negative Breast Cancer. Anticancer Res. 37(9):4845-4852;
[0564] Feniger-Barish, R. et al. (1999), Differential modes of regulation of cxcchemokine-induced internalization and recycling of human CXCR1 and CXCR2. Cytokine. 11(12):996-1009;
[0565] Garau, A. et al. (2005), Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine. 30(3):125-31;
[0566] Ginestier, C. et al. (2010), CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 120(2):485-97;
[0567] Ha, H., B. Debnath and N. Neamati (2017), Role of the CXCL8-CXCR1 / 2 Axis in Cancer and Inflammatory Diseases. Theranostics. 7(6):1543-1588;
[0568] Harada, A. et al. (1994), Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol. 56(5):559-64;
[0569] Highfill, S. L. et al. (2014), Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 6(237):237ra67;
[0570] Jamal, R. et al. (2017), Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin / paclitaxel in unresectable stage III or stage IV melanoma. J Immunother Cancer. 5(1):83;
[0571] Klussmann S. (2006). "The Aptamer Handbook–Functional Oligonucleotides and their Applications." Edited by S. Klussmann. WILEY-VCH, Weinheim, Germany, ISBN 3-527-31059-2;
[0572] Koch, A. E. et al. (1992), Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 258(5089):1798-801;
[0573] Kratschmer, C. and M. Levy, Effect of Chemical Modifications on Aptamer Stability in Serum. Nucleic Acid Ther, 2017. 27(6): p. 335-344;
[0574] Kusser W(2000). J Biotechnol 74:27-38;
[0575] Li, A. et al. (2005), Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis. 8(1):63-71;
[0576] Liu, Q. et al. (2016), The CXCL8-CXCR1 / 2 pathways in cancer. Cytokine Growth Factor Rev. 31: 61-71;
[0577] Ludwig, H. et al. (2017), Olaptesed pegol, an anti-CXCL12 / SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed / refractory multiple myeloma: a Phase IIa Study. Leukemia. 31(4): 997-1000;
[0578] Maxwell, P. J. et al. (2013), Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. Eur Urol. 64(2): 177-88;
[0579] Maxwell, P. J. et al. (2014), Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget. 5(13): 4895-4908;
[0580] McGinnis S, Madden TL (2004) BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res. 32(Web Server issue): W20-5;
[0581] Menne, J. et al. (2017), C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant. 32(2):307-315;
[0582] Merritt, W.M. et al. (2008), Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 100(5):359-72;
[0583] Morris, A.C. et al. (2009), Diagnostic importance of pulmonary interleukin-1β and interleukin-8 in ventilator-associated pneumonia. Thorax. thx. 2009.122291;
[0584] Needleman & Wunsch (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. 48(3):443-53;
[0585] Oberthur, D. et al. (2015), Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 6:6923;
[0586] Pearson & Lipman (1988) Improved tools for biological sequence comparison. Proc. Nat'l. Acad. Sci. USA 85:2444;
[0587] Russo, R.C. et al. (2014), The CXCL8 / IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 10(5):593-619;
[0588] Sanmamed, M.F. et al. (2014), Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res. 20(22):5697-707;
[0589] Sawant, K.V. et al. (2016), Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci Rep. 6:33123;
[0590] Shahzad, A. et al. (2010), Interleukin 8 (IL-8) - a universal biomarker? Int Arch Med. 3: p.11;
[0591] Skov, L. et al. (2008), IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol. 181(1):669-79;
[0592] Smith&Waterman (1981) Adv. Appl. Math. 2:482;
[0593] Steele, C.W. et al. (2016), CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell. 29(6):832-45;
[0594] Sung, H.J. et al., Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8. Biomaterials, 2014. 35(1): p.578-89;
[0595] Venkatesan N, Kim SJ, Kim BH(2003)Novel phosphoramidite building blocks in synthesis and applications toward modified oligonucleotides. Curr Med Chem 10(19):1973-1991;
[0596] Visvader, J.E. and G.J. Lindeman(2008), Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8(10):755-68;
[0597] Wang, C. et al. (2016), CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients. Sci Rep. 6:33569;
[0598] Wincott F, DiRenzo A, Shaffer C, Grimm S, Tracz D, Workman C, Sweedler D, Gonzalez C, Scaringe S, and Usman N (1995). Synthesis, deprotection, analysis and purification of RNA and ribosomes. Nucleic Acids Res. 23:2677-2684;
[0599] Xu, L. and IJ Fidler (2000), Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res. 12(2):97-106;
[0600] Yao, R. et al. (2015), Diagnostic performance of interleukin-6andinterleukin-8 for bacterial meningitis: a meta-analysis. Int J Clin Exp Med.8(5):7059-68;
[0601] Zhou, M. et al. (2015), Interleukin-8 for diagnosis of neonatal sepsis: ameta-analysis. PLoS One. 10(5):e0127170.
[0602] The project driving this application received funding from the European Union's Horizon 2020 research and innovation programme, grant agreement No 634415. Sequence Listing <110> Aptarion biotech AG <120> CXCL8 binding nucleic acid <130> A10064 PCT <150> EP 18 205 750.5 <151> 2018-11-12 <160> 45 <170> PatentIn version 3.5 <210> 1 <211> 77 <212> PRT <213> Artificial sequence <220> <223> synthesis <220> <221> MISC_FEATURE <222> (1)..(77) <223> D-amino acids <220> <221> MISC_FEATURE <222> (77)..(77) <223> Biotin-attached <400> 1 Ala Val Leu Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys 1 5 10 15 Thr Tyr Ser Lys Pro Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val 20 25 30 Ile Glu Ser Gly Pro His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu 35 40 45 Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln 50 55 60 Arg Val Val Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser 65 70 75 <210> 2 <211> 77 <212> PRT <213> people <220> <221> MISC_FEATURE <222> (1)..(77) <223> CXCL8 <400> 2 Ala Val Leu Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys 1 5 10 15 Thr Tyr Ser Lys Pro Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val 20 25 30 Ile Glu Ser Gly Pro His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu 35 40 45 Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln 50 55 60 Arg Val Val Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser 65 70 75 <210> 3 <211> 45 <212> RNA <213> Artificial sequence <220> <223> Synthetic <400> 3 gcugacggaa guacguggaa agccaaugag ugugucccgg ucagc 45 <210> 4 <211> 45 <212> RNA <213> Artificial sequence <220> <223> Syntetic <400> 4 gcugacggaa guacguggaa agccgaugag ugugucccgg ugagc 45 <210> 5 <211> 44 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 5 gcugacggaa guacguggaa agccgaaagu gugucccggu cagc 44 <210> 6 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 6 cugacggaag uacguggaaa gccgaaagugugucccgguc ag 42 <210> 7 <211> 40 <212> RNA <213> Artificial sequence <220> <223> Sythetic <400> 7 ugacggaagu acguggaaag ccgaaagugu gucccgguca 40 <210> 8 <211> 38 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 8 gacggaagua cguggaaagc cgaaagugu ucccgguc 38 <210> 9 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 9 gugacggaag uacguggaaa gccgaaagug ugacccgguc ac 42 <210> 10 <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 10 ggacggaagu acguggaaag ccgaaagugu gucccggucc 40 <210> 11 <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 11 gcacggaagu acguggaaag ccgaaagugu gucccggugc 40 <210> 12 <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 12 ggucggaagu acguggaaag ccgaaagugu gucccggacc 40 <210> 13 <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 13 uggcggaagu acguggaaag ccgaaagugu gucccggcca 40 <210> 14 <211> 45 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 14 gcugacggaa guacguggaa agccaaugag ugugucccgg ucagc 45 <210> 15 <211> 45 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 15 gcugacggaa guacguggaa agccgaugag ugugucccgg ugagc 45 <210> 16 <211> 44 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 16 gcugacggaa guacguggaa agccgaaagu gugucccggu cagc 44 <210> 17 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 17 cugacggaag uacguggaaa gccgaaagugugucccgguc ag 42 <210> 18 <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 18 ugacggaagu acguggaaag ccgaaagugu gucccgguca 40 <210> 19 <211> 38 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 19 gacggaagua cguggaaagc cgaaagugu ucccgguc 38 <210> 20 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 20 gugacggaag uacguggaaa gccgaaagug ugacccgguc ac 42 <210> twenty one <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> twenty one ggacggaagu acguggaaag ccgaaagugu gucccggucc 40 <210> twenty two <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> twenty two gcacggaagu acguggaaag ccgaaagugu gucccggugc 40 <210> twenty three <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> twenty three ggucggaagu acguggaaag ccgaaagugu gucccggacc 40 <210> twenty four <211> 40 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> twenty four uggcggaagu acguggaaag ccgaaagugu gucccggcca 40 <210> 25 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <223> PEG is attached to the 5' end via an aminohexyl group <400> 25 cugacggaag uacguggaaa gccgaaagugugucccgguc ag 42 <210> 26 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <223> An aminohexyl linker was attached to the 5' end <400> 26 cugacggaag uacguggaaa gccgaaagugugucccgguc ag 42 <210> 27 <211> 33 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <222> (21)..(21) <223> U is U or it does not exist <400> 27 ggaaguacgu ggaaagccra uragugugucccg 33 <210> 28 <211> 33 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 28 ggaaguacgu ggaaagccaa ugagugugucccg 33 <210> 29 <211> 33 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 29 ggaaguacgu ggaaagccga ugagugugucccg 33 <210> 30 <211> 32 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 30 ggaaguacgu ggaaagccga aagugugucc cg 32 <210> 31 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <400> 31 gacuggcccu gugugaaagc cgaaaggugc augaaggcag uc 42 <210> 32 <211> 73 <212> PRT <213> people <220> <221> MISC_FEATURE <222> (1)..(73) <223> CXCL1 <400> 32 Ala Ser Val Ala Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr Leu Gln 1 5 10 15 Gly Ile His Pro Lys Asn Ile Gln Ser Val Asn Val Lys Ser Pro Gly 20 25 30 Pro His Cys Ala Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Arg 35 40 45 Lys Ala Cys Leu Asn Pro Ala Ser Pro Ile Val Lys Lys Ile Ile Glu 50 55 60 Lys Met Leu Asn Ser Asp Lys Ser Asn 65 70 <210> 33 <211> 73 <212> PRT <213> human <220> <221> MISC_FEATURE <222> (1)..(73) <223> CXCL2 <400> 33 Ala Pro Leu Ala Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr Leu Gln 1 5 10 15 Gly Ile His Leu Lys Asn Ile Gln Ser Val Lys Val Lys Ser Pro Gly 20 25 30 Pro His Cys Ala Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Gln 35 40 45 Lys Ala Cys Leu Asn Pro Ala Ser Pro Met Val Lys Lys Ile Ile Glu 50 55 60 Lys Met Leu Lys Asn Gly Lys Ser Asn 65 70 <210> 34 <211> 73 <212> PRT <213> human <220> <221> MISC_FEATURE <222> (1)..(73) <223> CXCL3 <400> 34 Ala Ser Val Val Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr Leu Gln 1 5 10 15 Gly Ile His Leu Lys Asn Ile Gln Ser Val Asn Val Arg Ser Pro Gly 20 25 30 Pro His Cys Ala Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Lys 35 40 45 Lys Ala Cys Leu Asn Pro Ala Ser Pro Met Val Gln Lys Ile Ile Glu 50 55 60 Lys Ile Leu Asn Lys Gly Ser Thr Asn 65 70 <210> 35 <211> 78 <212> PRT <213> human <220> <221> MISC_FEATURE <222> (1)..(78) <223> CXCL5 <400> 35 Ala Gly Pro Ala Ala Ala Val Leu Arg Glu Leu Arg Cys Val Cys Leu 1 5 10 15 Gln Thr Thr Gln Gly Val His Pro Lys Met Ile Ser Asn Leu Gln Val 20 25 30 Phe Ala Ile Gly Pro Gln Cys Ser Lys Val Glu Val Val Ala Ser Leu 35 40 45 Lys Asn Gly Lys Glu Ile Cys Leu Asp Pro Glu Ala Pro Phe Leu Lys 50 55 60 Lys Val Ile Gln Lys Ile Leu Asp Gly Gly Asn Lys Glu Asn 65 70 75 <210> 36 <211> 77 <212> PRT <213> human <220> <221> MISC_FEATURE <222> (1)..(77) <223> CXCL6 <400> 36 Gly Pro Val Ser Ala Val Leu Thr Glu Leu Arg Cys Thr Cys Leu Arg 1 5 10 15 Val Thr Leu Arg Val Asn Pro Lys Thr Ile Gly Lys Leu Gln Val Phe 20 25 30 Pro Ala Gly Pro Gln Cys Ser Lys Val Glu Val Val Ala Ser Leu Lys 35 40 45 Asn Gly Lys Gln Val Cys Leu Asp Pro Glu Ala Pro Phe Leu Lys Lys 50 55 60 Val Ile Gln Lys Ile Leu Asp Ser Gly Asn Lys Lys Asn 65 70 75 <210> 37 <211> 94 <212> PRT <213> Human <220> <221> MISC_FEATURE <222> (1)..(94) <223> CXCL7 <400> 37 Ser Ser Thr Lys Gly Gln Thr Lys Arg Asn Leu Ala Lys Gly Lys Glu 1 5 10 15 Glu Ser Leu Asp Ser Asp Leu Tyr Ala Glu Leu Arg Cys Met Cys Ile 20 25 30 Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser Leu Glu Val 35 40 45 Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu 50 55 60 Lys Asp Gly Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys 65 70 75 80 Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala Asp 85 90 <210> 38 <211> 68 <212> PRT <213> people <220> <221> MISC_FEATURE <222> (1)..(68) <223> CCL5 <400> 38 Ser Pro Tyr Ser Ser Asp Thr Thr Pro Cys Cys Phe Ala Tyr Ile Ala 1 5 10 15 Arg Pro Leu Pro Arg Ala His Ile Lys Glu Tyr Phe Tyr Thr Ser Gly 20 25 30 Lys Cys Ser Asn Pro Ala Val Val Phe Val Thr Arg Lys Asn Arg Gln 35 40 45 Val Cys Ala Asn Pro Glu Lys Lys Trp Val Arg Glu Tyr Ile Asn Ser 50 55 60 Leu Glu Met Ser 65 <210> 39 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <222> (42)..(42) <223> PEG is attached via an aminohexyl linker <400> 39 cugacggaag uacguggaaa gccgaaagugugucccgguc ag 42 <210> 40 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <222> (42)..(42) <223> Aminohexyl linker attached <400> 40 cugacggaag uacguggaaa gccgaaagugugucccgguc ag 42 <210> 41 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <222> (1) <223> PEG is attached via an aminohexyl linker <400> 41 gugacggaag uacguggaaa gccgaaagug ugacccgguc ac 42 <210> 42 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <222> (1) <223> Aminohexyl linker attached <400> 42 gugacggaag uacguggaaa gccgaaagug ugacccgguc ac 42 <210> 43 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <222> (42)..(42) <223> PEG is attached via an aminohexyl linker <400> 43 gugacggaag uacguggaaa gccgaaagug ugacccgguc ac 42 <210> 44 <211> 42 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <222> (42)..(42) <223> Aminohexyl connector <400> 44 gugacggaag uacguggaaa gccgaaagug ugacccgguc ac 42 <210> 45 <211> 35 <212> RNA <213> Artificial sequence <220> <223> synthesis <220> <221> misc_feature <223> All C are 2' fluoro-C <220> <221> misc_feature <223> All U are 2'-fluoro-U <400> 45 gggggcuuau cauuccauuu aguguuauga uaacc 35
Claims
1. An L-nucleic acid molecule capable of binding to human CXCL8, wherein the nucleotide sequence of the L-nucleic acid molecule is selected from the following group: SEQ.ID.No: 16-17 and 20, wherein the nucleotide sequences of SEQ.ID.No: 16-17 and 20 are as follows: 。 2. The L-nucleic acid molecule of claim 1, wherein the L-nucleic acid molecule consists of ribonucleotides.
3. The L-nucleic acid molecule of claim 1, wherein the binding affinity of the L-nucleic acid molecule to human CXCL8 is 10 nM or less as expressed in KD. 4 . The L-nucleic acid molecule of claim 1 , wherein the binding affinity of the L-nucleic acid molecule to human CXCL8 is 10 nM or less as expressed in IC50.
5. The L-nucleic acid molecule of claim 1, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is 100 nM or higher, expressed as KD.
6. The L-nucleic acid molecule of claim 1, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is 100 nM or higher, expressed as IC50.
7. The L-nucleic acid molecule of claim 1, wherein the binding affinity of the L-nucleic acid molecule to human CXCL8 is expressed as 10 nM or less, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is expressed as 100 nM or more, and / or The binding affinity of the L-nucleic acid molecule to human CXCL8 is 10 nM or less as expressed in IC50, wherein the binding affinity of the L-nucleic acid molecule to an ELR-positive CXC chemokine other than CXCL8 is 100 nM or more as expressed in IC50.
8. The L-nucleic acid molecule of claim 3, wherein the binding affinity is determined at room temperature or at 25°C or 37°C.
9. The L-nucleic acid molecule of claim 4, wherein the binding affinity is determined at room temperature or at 25°C or 37°C.
10. The L-nucleic acid molecule of claim 5, wherein the binding affinity is determined at room temperature or at 25°C or 37°C.
11. The L-nucleic acid molecule of claim 6, wherein the binding affinity is determined at room temperature or at 25°C or 37°C.
12. The L-nucleic acid molecule of claim 7, wherein the binding affinity is determined at room temperature or at 25°C or 37°C.
13. The L-nucleic acid molecule of claim 1, wherein the L-nucleic acid molecule is an antagonist of human CXCL8-mediated activity. 14 . The L-nucleic acid molecule of claim 13 , wherein the antagonistic activity of the L-nucleic acid molecule against the activity mediated by human CXCL8 is 10 nM or less as expressed in IC50.
15. The L-nucleic acid molecule of claim 13, wherein the antagonistic activity of the L-nucleic acid molecule on the activity mediated by human CXCL8 is measured at 37°C.
16. The L-nucleic acid molecule of claim 1, wherein the L-nucleic acid molecule comprises a modifying group.
17. The L-nucleic acid molecule of claim 16, wherein the modifying group is coupled to the 5' terminal nucleotide and / or the 3' terminal nucleotide of the L-nucleic acid molecule.
18. The L-nucleic acid molecule of claim 16, wherein the modifying group is coupled to the L-nucleic acid molecule via a linker.
19. The L-nucleic acid molecule of claim 18, wherein the linker is a hydrophilic linker.
20. The L-nucleic acid molecule of claim 18, wherein the linker is a biodegradable linker.
21. The L-nucleic acid molecule of claim 16, wherein the excretion rate of the L-nucleic acid molecule comprising the modification group from an organism is reduced compared to the excretion rate of the L-nucleic acid molecule not containing the modification group.
22. The L-nucleic acid molecule of claim 16, wherein the L-nucleic acid molecule comprising the modification group has a retention time in the organism that is longer than the retention time in the organism that the L-nucleic acid molecule not comprising the modification group has.
23. The L-nucleic acid molecule according to claim 21, wherein the organism is a human or animal body.
24. The L-nucleic acid molecule according to claim 22, wherein the organism is a human or animal body.
25. The L-nucleic acid molecule of claim 16, wherein the modifying group consists of polyethylene glycol.
26. The L-nucleic acid molecule according to claim 25, wherein the polyethylene glycol is a linear polyethylene glycol or a branched polyethylene glycol.
27. The L-nucleic acid molecule according to claim 26, wherein the molecular weight of the polyethylene glycol is from 20,000 to 120,000 Da.
28. The L-nucleic acid molecule according to claim 16, wherein the modification group is used for the immobilization of the L-nucleic acid molecule.
29. The L-nucleic acid molecule of claim 28, wherein said immobilization comprises covalent attachment of said L-nucleic acid molecule to a surface.
30. The L-nucleic acid molecule according to claim 29, wherein the surface is a surface of a reaction vessel, a surface of a device in a reaction vessel or a surface of a biosensor.
31. The L-nucleic acid molecule of claim 28, wherein said immobilization comprises non-covalent attachment of said L-nucleic acid molecule to a surface.
32. The L-nucleic acid molecule according to claim 31, wherein the surface is a surface of a reaction vessel, a surface of a device in a reaction vessel or a surface of a biosensor.
33. The L-nucleic acid molecule of claim 28, wherein the modification group is a strained cycloalkyne.
34. The L-nucleic acid molecule of claim 33, wherein the strained cycloalkyne is dibenzocyclooctyl (DBCO).
35. The L-nucleic acid molecule of claim 31, wherein the modifying group is biotin, bromodeoxyuridine, digoxigenin or an oligonucleotide.
36. The L-nucleic acid molecule of claim 35, wherein the modifying group is biotin.
37. The L-nucleic acid molecule of claim 16, wherein said modification group allows for detection of said L-nucleic acid molecule.
38. The L-nucleic acid molecule of claim 37, wherein the modifying group is a label.
39. The L-nucleic acid molecule of claim 38, wherein the label is selected from the group consisting of biotin, bromodeoxyuridine, digoxigenin, oligonucleotides, fluorescent labels, electrochemiluminescent labels, radioactive labels, enzyme labels, UV labels, colloidal gold, nanoparticles, and chelator molecular labels.
40. The L-nucleic acid molecule of claim 1, wherein the L-nucleic acid molecule consists of a sequence selected from the group consisting of: SEQ.ID.No:25-26 and 39-44, wherein the sequences of SEQ.ID.No:25-26 and 39-44 are as follows: 。 41. A pharmaceutical composition comprising an L-nucleic acid molecule as defined in any one of claims 1 to 40 and optionally further components, wherein the further components are selected from the group comprising a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier and a pharmaceutically active agent.
42. The pharmaceutical composition of claim 41, wherein the pharmaceutical composition comprises an L-nucleic acid molecule as defined in any one of claims 1 to 40 and a pharmaceutically acceptable carrier.
43. Use of an L-nucleic acid molecule according to any one of claims 1 to 40 for the preparation of a medicament.
44. The use according to claim 43, wherein the medicament is for use in human medicine or for use in veterinary medicine.
45. Use of an L-nucleic acid molecule according to any one of claims 1 to 40 for the preparation of a diagnostic agent or a biosensor.
46. The use of claim 45, wherein the diagnostic agent has a surface on a reaction vessel or a surface on a device in a reaction vessel.
47. The use of claim 45, wherein the biosensor has a surface.
48. The use of claim 45, wherein the diagnostic agent or biosensor is suitable for directly or indirectly detecting human CXCL8.
49. The use of claim 48, wherein human CXCL8 is detected by direct binding in a sandwich binding assay or in a competition binding assay.
50. The use according to claim 49, wherein the direct binding comprises a detection method using only the L-nucleic acid molecule of claim 1.
51. The use of claim 49, wherein the sandwich assay is a sandwich hybridization assay, wherein the L-nucleic acid molecule of claim 1 is immobilized on a surface and the complex of the L-nucleic acid molecule of claim 1 and human CXCL8 is detected by a detection molecule specific for CXCL8, wherein the detection molecule binds one or more epitopes of human CXCL8 that are different from the one or more epitopes bound by the L-nucleic acid molecule of claim 1.
52. The use of claim 49, wherein the sandwich assay is a sandwich hybridization assay, wherein a detection molecule specific for CXCL8 is immobilized on a surface, the detection molecule binding one or more epitopes of human CXCL8 being different from the one or more epitopes bound by the L-nucleic acid molecule of claim 1, and the complex of this detection molecule and human CXCL8 is detected by the L-nucleic acid molecule of claim 1.
53. The use of claim 49, wherein in the competitive binding assay, the L-nucleic acid molecule of claim 1 is immobilized on a surface, and the binding of the L-nucleic acid molecule of claim 1 to human CXCL8 is competed by an oligonucleotide probe complementary to the L-nucleic acid molecule of claim 1 or human CXCL8.
54. The use of claim 49, wherein in the competitive binding assay, the L-nucleic acid molecule of claim 1 is not immobilized on a surface, and the binding of the L-nucleic acid molecule of claim 1 to human CXCL8 is competed by an oligonucleotide probe complementary to the L-nucleic acid molecule of claim 1 or human CXCL8.
55. The use according to claim 51, wherein the L-nucleic acid molecule according to claim 28 is used for immobilization on the surface.
56. The use according to claim 53, wherein the L-nucleic acid molecule according to claim 28 is used for immobilization on the surface.
57. The use of claim 46, wherein the surface is selected from the group consisting of gold, silver, titanium, zirconium, vanadium, chromium, manganese, cobalt, tungsten, molybdenum, platinum, aluminum, iron, steel, copper, nickel, silicon, germanium, indium phosphide, gallium arsenide, and oxides, nitrides or alloys or mixtures thereof, indium tin oxide, glassy carbon, sapphire, silicate glass, and borate glass.
58. The use according to claim 57, wherein the surface is the surface of a biosensor.
59. The use of claim 46, wherein the surface is modified by polylysine, aminosilane, nitrocellulose, carboxydextran, nanocarbon film, graphene oxide, carbon surface, carboxyl, azido, thiol, hydroxyl, epoxide, maleimide, alkyne or any combination thereof.
60. The use of claim 59, wherein the surface is modified by epoxysilane or strained alkyne.
61. The use of claim 59, wherein the carbon surface is carbon black, carbon fiber, carbon plate, carbon cloth, activated carbon, glassy carbon, charcoal, graphite powder, graphite fiber, carbon nanotube, fullerene or any combination thereof.
62. The use of claim 61, wherein the carbon surface is activated charcoal.
63. The use of claim 59, wherein the surface is the surface of a biosensor.
64. The use according to claim 59, wherein for the immobilization of the L-nucleic acid molecules according to claim 28, the surface is functionalized by primary amines, thiol groups, azides, alkynes, alkenes, tetrazines or tetrazoles.
65. The use of claim 64, wherein the surface is functionalized by a strained cycloalkyne.
66. The use of claim 65, wherein the strained cyclic alkyne is selected from the group consisting of dibenzocyclooctyl (DBCO), bicyclo[6.1.0]non-4-yne (BCN) or azadibenzocyclooctyne (ADIBO).
67. The use according to claim 66, wherein for the immobilization of the L-nucleic acid molecule according to claim 33 a strain-promoted azide-alkyne cycloaddition reaction is used.
68. The use according to claim 45, wherein the L-nucleic acid molecule according to claim 35 is used for detection.
69. The use of claim 45, wherein the detection system of the biosensor is based on optical readout, mass change, refractive index, charge, surface stress and atomic force microscopy.
70. The use of claim 69, wherein the detection system of the biosensor based on optical readout is fluorescence, absorption or luminescence.
71. The use of claim 69, wherein the detection system of the mass change-based biosensor is a quartz crystal microbalance or a micro-electromechanical system.
72. The use of claim 69, wherein the detection system of the refractive index based biosensor is surface plasmon resonance, ring resonator or ellipsometry.
73. The use of claim 69, wherein the detection system of the charge-based biosensor is electrochemical impedance, voltammetry, amperometry, potentiometry, conductivity, or field effect transistor.
74. The use of claim 69, wherein the detection system of the surface stress-based biosensor is a cantilever biosensor.
75. The use of claim 45, wherein human CXCL8 is detected by a homogenous assay setup.
76. A kit for detecting human CXCL8, wherein the kit comprises the L-nucleic acid molecule according to any one of claims 1 to 40, and at least instructions or a reaction container.
77. Use of an L-nucleic acid molecule as defined in any one of claims 1 to 40 for preparing a preparation for a method for detecting human CXCL8 in a sample, wherein the method comprises the following steps: a) providing a sample with an unknown concentration of human CXCL8; b) contacting the sample or a dilution thereof with a diagnostic agent or a biosensor as defined in claim 45; c) Measuring a signal using a diagnostic agent or a biosensor as defined in claim 45.
78. The use of claim 77, wherein the method further comprises comparing the signal to a reference.
79. The use of claim 77 or 78, wherein the method further comprises determining the concentration of human CXCL8 in a sample having an unknown human CXCL8 concentration by comparison with a signal obtained from at least one sample having a known human CXCL8 concentration.
80. A complex comprising the L-nucleic acid molecule of any one of claims 1 to 40 and human CXCL8.
